Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with considerable heterogeneity reflected in the 2008 World Health Organization classification. In recent years, genome-wide assessment of genetic and epigenetic alterations has shed light upon distinct molecular subsets linked to dysregulation of specific genes or pathways. Besides fostering our knowledge regarding the molecular complexity of DLBCL types, these studies have unraveled previously unappreciated genetic lesions, which may be exploited for prognostic and therapeutic purposes. Following the last World Health Organization classification, we have witnessed the emergence of new variants of specific DLBCL entities, such as CD30 + DLBCL, human immunodeficiency virus-related and age-related variants of plasmablastic lymphoma, and EBV + DLBCL arising in young patients. In this review, we will present an update on the clinical, pathologic, and molecular features of DLBCL incorporating recently gained information with respect to their pathobiology and prognosis. We will emphasize the distinctive features of newly described or emerging variants and highlight advances in our understanding of entities presenting a diagnostic challenge, such as T-cell/histiocyte-rich large Bcell lmphoma and unclassifiable large B-cell lymphomas. Furthermore, we will discuss recent advances in the genomic characterization of DLBCL, as they may relate to prognostication and tailored therapeutic intervention. The information presented in this review derives from English language publications appearing in PubMed throughout December 2015. For a complete outline of this paper, please visit: http://links.lww.com/PAP/A12. targeted irrespective of the COO. 52 Notably, there remains marked heterogeneity within both GCB and ABC groups, 39 which needs to be elucidated for therapeutic purposes. ABC DLBCL indicates activated B-cell type-diffuse large B-cell lymphoma; Amp, amplification; BCL6 BSE1, BCL6-binding site within exon 1; D, deletion; GCB-DLBCL, germinal center B-cell type-diffuse large B-cell lymphoma; M, mutation; Tx, translocation.
D iffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma (NHL) accounting for 30% for 40% of all newly diagnosed lymphomas. It is a group of disparate entities with marked differences in phenotype and molecular pathogenesis and a highly variable clinical course. 1 The diversity of this group is reflected in the World Health Organization (WHO) classification, 2 which lists 22 subgroups, variants, subtypes, or entities defined by morphology, immunophenotype, clinical parameters, or molecular features ( Table 1) . Some of these lymphomas originate preferentially or exclusively in extranodal sites, such as primary cutaneous large B-cell lymphoma (PCLBCL), intravascular large B-cell lymphoma (IVLBCL), primary DLBCL of the central nervous system (CNS), lymphomatoid granulomatosis (LYG), or primary mediastinal large B-cell lymphoma (PMLBCL). 3 From a morphologic point of view they are typified by a diffuse growth of large B cells with a nuclear size at least equal to that of the normal macrophage nucleus or more than twice the size of the small lymphocyte. 2 A significant proportion of cases defy assignment into any specific subgroup/subtype and are designated DLBCL not otherwise specified (NOS). Despite ongoing progress in unraveling the molecular heterogeneity of this entity, translation to effective personalized treatment strategies remains as yet challenging. 4, 5 Some of these entities are defined according to the presumed cell of origin (COO), for example, the group of terminally differentiated LBCLs. This, however, is not applicable to certain subtypes, such as IVLBCL, lacking an obvious normal cell counterpart. For a number of DLBCL types, emphasis has been put on the pathogenetic mechanisms, including driver oncogenic translocations as in the case of ALK + LBCL, chronic inflammation, or viruses involved in B-cell transformation, as in the case of Epstein-Barr viruspositive (EBV + ) DLBCL or primary effusion lymphoma (PEL). 5 During the last few years following WHO classification, we have witnessed the emergence of new variants, such as CD30 + DLBCL, human immunodeficiency virus (HIV)-related and age-related variants of plasmablastic lymphoma (PBL), early and extracavitary variants of PEL, or EBV + DLBCL in young patients, which underlie the heterogeneity even within specific DLBCL entities. The present review aims to summarize recent information gained from gene expression studies with regard to pathogenesis and prognosis of the various DLBCL entities listed in WHO classification, to discuss the newly described or emerging variants in terms of distinctive pathologic, molecular, and clinical characteristics as well as to highlight advances in our understanding of entities presenting a diagnostic challenge, such as T-cell/histiocyte-rich LBCL (THRLBCL) and unclassifiable large B-cell lymphomas (BCLu).
DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
This is a diagnosis of exclusion. It is undoubtedly the most common type of aggressive LBCLs accounting for 25% to 30% of NHLs. It is more often diagnosed in elderly individuals with a slight male predominance and may arise de novo or in the setting of transformation from a preexisting low-grade B-cell lymphoma (so-called "secondary" DLBCL). Patients usually present with a rapidly enlarging lymph node (70%) or extranodal mass (30%), the most commonly involved extranodal sites being the gastrointestinal (GI) tract and the Waldeyer ring. However, in half of the cases the disease is localized, and in only one third of them are B symptoms or bone marrow involvement at diagnosis present. 3, [5] [6] [7] The latter may be of concordant or discordant histology and carries an adverse prognosis, particularly if it is of concordant histology. 8 The standard initial treatment for DLBCL patients is R-CHOP. 9 Although durable remissions can be achieved in the majority of cases [5-y progression-free survival (PFS) 50% to 65%], 30% to 40% of patients will develop relapse with refractory disease. A possible explanation is the considerable biological heterogeneity of DLBCL as discussed below. Thus, in addition to classic morphology and immunophenotypic analysis, the diagnosis necessitates the integration of new molecular diagnostic tools.
From a morphologic point of view, 3 main variants are recognized: centroblastic, immunoblastic, and anaplastic. 2 Centroblasts display multiple nucleoli adjacent to the nuclear membrane, whereas immunoblasts show a prominent central nucleolus and copious eosinophilic cytoplasm. Lymphomatous cells grow diffusely, partly or completely effacing the normal architecture of lymph node or extranodal site. On occasions, an interfollicular or intrasinusoidal growth pattern is encountered raising the differential diagnosis with marginal zone lymphoma or anaplastic large cell lymphoma (ALCL), respectively. As a rule, there is a high mitotic and apoptotic activity, the latter giving rise to a "starry-sky" pattern. There is a variable number of small T cells, which, however, do not overshadow the neoplastic cells as in THRLBCL. Cases with >90% immunoblasts are diagnosed as immunoblastic variant, and in such instances plasmacytic differentiation may be obvious. 7 Given that the vast majority of cases contain a mixture of the 2 main cell types and cells with features intermediate between centroblasts and immunoblasts, cytologic subclassification is optional. 3 However, pure immunoblastic morphology is considered a negative prognostic parameter, even more relevant than the immunohistochemical (IHC) algorithms, 10 despite it being encountered in only 7.4% of the cases, which limits its prognostic utility. 1, 11 The immunoblastic variant is enriched for activated B-cell (ABC)-type cases. 12 Most recently, even the presence of a large proportion of immunoblasts, with or without plasmacytoid features, has been associated with poor prognosis in young high-risk patients. 13 The anaplastic variant bears resemblance to ALCL in terms of growth pattern and cytology. Multilobated cells are often encountered in extranodal lymphomas, such as primary bone DLBCL or PCLBCL. 7 Rare morphologic variants with myxoid stroma, signet-ring cells, or spindle cell morphology raising concern of metastatic carcinoma or sarcoma have also been described. 3 The neoplastic cells express the pan-B-cell markers CD20, CD79a, PAX5 in 98% of the cases. CD20 À DLBCL occurring in immunocompetent patients is enriched for non-GCB cases, displays a higher proliferation rate, a propensity for extranodal involvement, and a lower response rate to treatment compared with the CD20 + counterpart. 14 However, CD20 is negative in 60% of the cases following rituximab and may also be downregulated in the presence of plasmacytic differentiation. Monotypic cytoplasmic immunoglobulin cIg is recorded in 50% to 75% (cIgM > cIgG > cIgA) 1 and CD5 positivity in B10% of DLBCL cases arising de novo. Aberrant cytoplasmic CD3 expression is noted rarely, mostly in extranodal DLBCL, as well as in those with plasmacytic differentiation, and is usually not accompanied by other T-cell markers. 11, 15 Commonly expressed markers are CD10 (30% to -60%), bcl6 (60% to 90%), and MUM1 (35% to 65%). CD10 and bcl6 along with the newer GCET1, LMO2, HGAL, and MEF2B are germinal center (GC) markers, whereas MUM1, FOXP1, and CD138 post-GC markers. 11, 16, 17 Cyclin D1 expression is seen in B2% of DLBCL, usually in association with centroblastic morphology and MUM1 positivity, raising the differential diagnosis with pleomorphic mantle cell lymphoma (MCL). In contrast to the latter, cyclin D1 in DLBCL is expressed by a subset of the neoplastic cells often weakly and is not due to t (11;14) . 18, 19 Bcl2 is overexpressed in 44% to 80% of cases without an underlying t (14;18) , [20] [21] [22] [23] with SP66 clone being superior to Mab124. 24 CD30 positivity is noted in 10% to 40% of DLBCL, [25] [26] [27] [28] often in the anaplastic variant but also in some specific types such as LYG, pyothorax-associated lymphoma (PAL), PMLBCL, PBL, some BCLus, and EBV + DLBCL of the elderly (EBV + DLBCL-e). 1 p53 is expressed in 20% to 60% of the cases. 2 Ki67 index varies widely, but in the presence of >90% immunoreactivity it is advisable to search for MYC rearrangements. 7 CD43 is expressed in 25% of DLBCLs in association with the non-GCB type. 29 Lastly, in cases with Hodgkin/Reed-Sternberg (HRS)-like cells and geographic necrosis, it is recommended to test for EBV by in situ hybridization [EBV-encoded small RNA (EBER)], in order to exclude the possibility of EBV + DLBCL.
Cell of Origin Determination by Immunohistochemistry
The prognostic impact of COO by gene expression profiling (GEP) (discussed below) has prompted the emergence of a variety of IHC algorithms aiming to recapitulate the COO in formalin-fixed paraffin-embedded tissue in daily routine. These algorithms are based on antigens expressed by GC B cells and activated B cells. Although in general these IHC approaches concur with molecular methods with regard to COO assignment, they cannot be relied upon as surrogate 30 ( Table 2 ). The most popular of these approaches is the Hans classifier using CD10, bcl6, and MUM1 and showing an 80% to 86% concordance rate with GEP signatures. 31 Modifications of this algorithm have been made in an attempt toward more accurate COO determination. [32] [33] [34] [35] The most promising of these classifiers appears to be the Visco-Young algorithm, 36 in which MUM1 is replaced by FOXP1 in the original Hans classifier, thus raising the accuracy rate to 92.6%. More importantly, this algorithm is able to stratify R-CHOP-treated patients into prognostically different groups. A recent metaanalysis argues against the prognostic utility of Hans and Choi algorithms and stresses the importance of molecularly assigned COO groups in this regard. 37 
Cell of Origin Determination by Molecular Methods
Gene expression microarrays before rituximab era identified at least 2 distinct subsets of DLBCL: the GC Bcell-like (GCB) group characterized by high expression of genes expressed in normal GCB cells and the ABC group enriched for genes normally expressed by activated B cells. A third group also emerged, so-called "type 3," the GEP of which was reminiscent of classical Hodgkin lymphoma (cHL). This group was thought to correspond to PMLBCL but also probably included cases with a low tumor cell content. 38, 39 Even when PMLBCL cases were removed, there remained a subset of 10% to 15% "unclassifiable" cases. The distinction of GCB and ABC molecular subgroups has profound biological, prognostic, and therapeutic implications, with the GCB subgroup having a favorable prognosis and the ABC group an adverse outcome even after the therapeutic institution of rituximab. 37, [40] [41] [42] [43] [44] Originally, these groups were defined on the basis of GEP using cDNA microarrays on RNA extracted from frozen tissue. 40, 45 This is considered to be the gold standard for COO assignment because of its robustness and consistency among various research groups. In recent years, new real-time COO assignment methods have been created applicable in formalin-fixed paraffin-embedded tissue, including quantitative nuclease protection assay, 46 multiplex reverse transcription polymerase chain reaction (RT-PCR), 47 cDNA-mediated annealing selection extension ligation (DASL) platform, 48 and nanonstring platform. 49 The latter assay utilizes a more simplified digital 20-gene gene classifier (Lymph2Cx) and shows >95% concordance with standard GEP methods as well as excellent interlaboratory concordance. 50 When this assay was applied in a large number of R-CHOP-treated patients, 32% of cases fell within the ABC group with a 5-year PFS of 48%, 56% fell within the GCB group with a 5-year PFS of 73%, and 11% remained unclassified. 50 Prognostic correlations were in fact slightly more pronounced using the Lymph2Cx assay than using the frozen tissue GEP because of the ability of this assay to resolve more unclassifiable cases into ABC and GCB subgroups. COO designation remains prognostically relevant even in the context of MYC/bcl2 expression status. 24, 51 It should be emphasized, though, that none of these assays is able to identify all patients who will be cured or will fail to respond to R-CHOP within each group. 52 In addition, some alterations are shared by both groups and may, therefore, be *The threshold for positivity for each marker is set at 30% except for bcl2 in the Muri algorithm, which is categorized on the basis of 50%.
w"Other" type in the Nyman algorithm is not clearly equivalent to GCB type.
zLMO2 is used only if the GC score (using CD10, GCET) and the non-GCB score (using MUM1 and FOXP1) are equivalent.
COO indicates cell of origin; GCB, germinal center B cell.
Genetic Lesions in Diffuse Large B-cell Lymphoma, Not Otherwise Specified
Compared with other mature B-cell lymphomas, DLBCL shows a considerably higher degree of genomic complexity including point mutation and copy number aberrations (CNA) and less frequently chromosomal translocations and gene amplifications. 53 Targeted genetic examination and genome-wide studies have revealed a variety of genetic aberrations preferentially associated with or exclusive to GCB or ABC types, while some of them may be seen in both groups ( Table 3) .
The GCB type of DLBCL is characterized by: chromosomal translocations of BCL2 (35% to 45%) and MYC (10% to 14%), both of which lead to overexpression of the respective protein, partly because they allow escape from bcl6-mediated transcriptional repression; PTEN deletions (B10%), mutations (3% to 22%), or epigenetic inactivation resulting in PI3K/AKT pathway activation and playing critical roles in the regulation of DNA repair, cellular senescence, cell migration, and stem cell-self renewal 54 ; EZH2 mutations (B22%); and mutations in the Ga13 pathway (B20%), which regulates the growth and local confinement of GCB cells. 53 BCL2 rearrangement due to t(14;18) is a hallmark of the GCB type of DLBCL (besides follicular lymphoma) corresponding to the transformation pathway. 55 These cases may have developed through transformation of a (known or occult) follicular lymphoma. BCL2 mutations are exclusive to GCB DLBCL due to aberrant somatic hypermutations and are associated with the presence of t (14;18) . 38 Those targeting the promoter region result in loss of bcl6 suppression by bcl2, whereas those affecting the coding part of the gene probably alter the interaction of bcl2 with p53 protein. 38 BCL2 rearrangements are absent in DLBCL occurring in patients under 18 years and are rare in DLBCLs arising in the Waldeyer ring. BCL2 amplification, in contrast, is recorded in 30% to 40% of ABC DLBCL cases. Bcl2 expression is also more frequent in ABC than in GCB type 20 as a result of NF-kB activation 56 irrespective of BCL2 gene amplification. 57 Bcl2 functions as an antiapoptotic factor conferring chemoresistance. This adverse effect was noted in the ABC DLBCL cases before rituximab, 57 whereas after the addition of rituximab it is elicited only in GCB cases. 20 The influence of rituximab on the prognostic impact of bcl2 may be explained by the downregulation of NF-kB and its target bcl2 only in ABC DLBCL resulting in increased susceptibility to chemotherapy. In contrast, in GCB DLBCL the expression of bcl2 is not downregulated by rituximab, and in synergy with bcl6 it will repress DNA damage response genes conferring resistance to drug-induced apoptosis. 20 The Bcl2 À group is associated with stromal-1 signature and a higher proliferation rate, whereas the bcl2 + group is enriched for T-follicular helper (TFH) cell-related signatures. 20 Bcl2 overexpression on its own has been recently reported as an adverse prognosticator in patients with low International Prognostic Index (IPI). 58 EZH2 gain-of-function somatic mutations are restricted to GCB-type DLBCL cases, especially those bearing t(14;18) 53 and promote trimethylation of histone 3 on lysine 27, which leads to transcriptional silencing. However, high levels of EZH2 are common in both GCB and ABC types. 59 EZH2 inhibitors have shown clinical promise in GCB DLBCL. 38 GCB-type DLBCL shows MDM2 amplification in 10% of the cases resulting in downregulation of the tumor suppressor p53. 60 Recently, recurrent amplification of 2p has been identified in 30% of GCB DLBCL cases, which are hypothesized to affect Rel coding for a subunit of NF-kB. 38, 53, 61 MYC located at 8q24 is a transcriptional factor exerting a global effect on a wide array of genes (10% to 15% of all human genes) and miRNAs. 62 It functions by forming heterodimers with MAX, which usually upregulate and less often repress the activity of target genes. MYC activation has profound influence on many different cell processes, such as cell proliferation/growth through regulation of cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors, DNA replication, metabolism/energy regulation, and protein/nucleotide biosynthesis. It also activates cell death pathways promoting apoptosis through downregulation of BCL2 and induction of p53 (reviewed in Karube and colleagues [62] [63] [64] ). As mature B cells do not express MYC because of repression by BCL6/Blimp1 it is speculated that the overexpression of MYC requires potent oncogenic events overcoming the inhibitory effect of those transcriptional factors. 62 Oncogenic mechanisms resulting in MYC activation in DLBCL include translocations (5% to 14%), amplification (2%), low (3 to 4) copy number gains (19% to 38%), and mutations (32%). 62 Increased MYC copy number is associated with high mRNA levels and increased relapse rate, 65, 66 although there appears to be no prognostic difference between low copy number gains and amplification (Z5 copies). 67 Mutations are often seen in MYC-rearranged cases in which they enhance MYC transforming capacity by stabilizing its protein or inhibiting the proapoptotic effect. 62, 64 High protein levels (usually defined as positivity in >40% of the neoplastic population) are recorded in 29% to 47% of DLBCLs, often (40%) in the absence of underlying MYC abnormalities, 21,23,66,68 this 
pointing toward other mechanisms sustaining MYC activation. 69 Ruzinova et al 70 claim that the presence of a nuclear (with or without cytoplasmic) localization of MYC protein is highly predictive of an MYC translocation. Despite the good correlation between increased (> 70%) MYC expression and the presence of gene rearrangements 71,72 the reverse is not true, as MYC translocations have been identified in up to 17% of cases with <30% MYC protein-positive cells. 73 Therefore, MYC IHC may be used as a screening tool, but because of its suboptimal specificity and positive predictive value, despite good sensitivity and negative predictive value, 74, 75 it is recommended to test cases with >30% positive cells by fluorescence in situ hybridization (FISH), 76 using an MYC break-apart probe. The MYC/IGH dual-fusion probe is useful to exclude the possibility of false-negative cases and to confirm the MYC partner. 77, 78 A significant subset (58% to 83%) of MYC-rearranged cases also harbor BCL2 and/or BCL6 rearrangements, so-called double-hit or triple-hit lymphomas (DHL or THL). 23, 66, 79, 80 Importantly, in contrast to Burkitt lymphoma (BL), MYC translocations in DLBCL are encountered within the context of complex genetic alterations, and in 35% to 53% the translocation partner is a non-IG gene. 62 Most MYC-rearranged cases with or without BCL2 rearrangements fall into the GCB subtype 81 with frequent CD10 and bcl6 expression and lack of MUM1 expression and are associated with a higher proliferation rate and a propensity for CNS, bone marrow, or extranodal site involvement. 82 Intriguingly, MYC/bcl2 coexpression is associated with the ABC type, the poor prognosis of which appears to be dictated by this double hit phenotype. 22 In the presence of MYC overexpression, COO determination reportedly does not impact on survival. 72 Two recent studies highlight a higher prevalence of MYC translocations in DLBCL with immunoblastic morphology (33% to 39%) compared with other cytologic variants (7%). 83 In most (77%) of these cases, MYC translocations constitute the sole abnormality, so-called single-hit lymphomas (SHL), whereas in all rearranged cases the MYC partner is IGH. 73 MYC gene abnormalities or protein/ mRNA overexpression have been validated as independent adverse prognosticators in a recent meta-analysis, 84 although neither appears to be sufficient as a single biomarker, as they are dependent upon the concurrent BCL2 and/or BCL6 gene abnormalities or deregulation of the respective protein expression. [21] [22] [23] 72, 85, 86 The adverse effect of MYC rearrangements is attenuated in young high-risk patients, whereas that of BCL2 rearrangement remains. 13 The adverse prognostic impact of MYC rearrangements is likely secondary to the IGH translocation partner. 81 74 Other investigators, however, have disputed this finding. 23, 83, 87, 88 Compared with DHL, SHL cases are distinguished by a higher rate and level of p53 immunoreactivity, a lower frequency of GCB immunophenotype, and IGH as the main MYC translocation partner advocating that MYC translocation could be the disease driver as in BL. 89 The ABC type of DLBCL is associated with: the NF-kB pathway activation promoting cell survival, proliferation, and inhibition of apoptosis 56 ; chronic active Bcell receptor (BCR) signaling resulting from CARD11 activating mutations (10%) and/or mutations in the Ig superfamily members CD79B or less often CD79A (> 20%) and triggering multiple downstream signaling cascades besides canonical NF-kB; and block in terminal B-cell differentiation. Additional abnormalities include amplification of the BCL2 locus (30% to 40%) and deletion or lack of expression of the CDKN2 tumor-suppressor genes (24% to 30%), which normally inhibit CDKs arresting the cell in the G1/S restriction point. 53 CARD11 along with BCL10 and MALT1 forms a signaling complex, called CBM complex, which is critical for ABC DLBCL cell survival and c-Jun N-terminal kinase signaling cascade. 90 An alternative mechanism of NF-kB activation is seen in 30% of the cases, which harbor biallelic mutations or deletions inactivating TNFAIP3 (A20), a negative regulator of NF-kB. 91 The third mechanism activating NF-kB signaling is the presence of MYD88 mutations in the Toll/ IL-1 receptor domain, which also mediate survival of neoplastic cells and trigger JAK/STAT signaling. In one third of MYD88 mutant DLBCL cases, CD79A or CD79B mutations are also recorded, denoting that these alterations are functionally nonredundant. 53, 61 Overall, these multiple genetic abnormalities culminating in NF-kB activation may afford the opportunity for novel molecularly targeted therapies, for example, Bruton tyrosine kinase inhibitor ibrutinib 92 or NF-kB signaling inhibitors such as bortezomib and lenalidomide. 41, [93] [94] [95] Deregulation of the master regulator of plasma cell differentiation PRDM1/Blimp1 due to truncating mutations, missense mutations, and/or genomic deletions is seen in one fourth of ABC DLBCLs, thereby preventing terminal differentiation (reviewed in Pasqualucci and Dalla-Favera 53 ). PRDM1 may also be repressed at the transcriptional level by BCL6 rearrangements, which appear to be mutually exclusive with PRDM1 alterations. 96 Genetic lesions common to GCB and ABC DLBCL include alterations of histone-modifying genes, BCL6 deregulation, loss of immune surveillance mechanisms, and abrogations of tumor suppressors such as p53 and FOXO1. 38, 53 Mutations in chromatin modifiers CREBBP, EP300, MLL2, and MLL3 are detected preferentially in GCB type (39% vs. 17% in the ABC type), emerging as a novel molecular hallmark of GC-derived B-cell lymphomas. 97 These alterations mainly contribute to lymphomagenesis through impaired acetylation of bcl6 and p53 causing constitutive activation of the former and inactivation of the latter. One consequence of impaired balance between bcl6 and p53 would be an increased tolerance for genomic instability sustained by the absence of proper apoptotic function. 38, 53 MLL2 encodes for a methyltransferase promoting the modification of histone 3 on lysine 4. MLL2 mutations generate severely truncated proteins devoid of methylating activity, which has a major impact on the epigenome of the precursor neoplastic cell. 38, 53 Alterations deregulating BCL6 represent a key mechanism of lymphomagenesis in DLBCL and are of particular importance in the de novo pathway of neoplastic transformation. Chromosomal rearrangements occur in 35% of DLBCL cases but are at least twice as frequent in ABC compared with GCB type 98 and prevent BCL6 silencing at the GC exit. In addition, BCL6 is targeted by point mutations in >70% of DLBCL cases but those clustered in the first BCL6 noncoding region deregulate bcl6 expression by at least 2 mechanisms. They disrupt the negative autoregulatory loop controlling BCL6 transcription and prevent IRF4 binding and transcriptional repression. 53, 99 BCL6 mutations are exclusive to GCB DLBCL suggesting that BCL6-mediated lymphomagenesis may exploit different mechanisms in DLBCL molecular subtypes. In addition to genetic lesions directly affecting the BCL6 gene, gain-of-function somatic mutations in the MEF2B (10% to 15% of cases) deregulate BCL6 activity at the transcriptional level. 100 Bcl6 expression is reportedly a favorable prognosticator in DLBCL, 23, 101, 102 whereas BCL6 translocations may imply an inferior survival probability perhaps due to their prevalence in ABC type. 103, 104 A recent large study, however, has failed to assign any prognostic utility to BCL6 translocations. 102 Around 60% of DLBCLs lack b2-microglobulin either due to mutations/deletions of the corresponding gene or to epigenetic mechanisms. As b2-microglobulin is a subunit of the HLA class I complex, these alterations result in lack of expression of HLA class I molecules by DLBCL cells enabling evasion from T/NK cell-mediated immune surveillance. 105 Other genetic events contributing to immune escape are MHC class II gene deletions (more frequent in DLBCLs arising in immune privileged sites such as CNS and testis), CIITA disruption, CD58 inactivation, particularly in ABCtype (68%) compared with GCB-type DLBCL, TNFSF9 inactivation (20%), and FAS mutations/deletions (5% to 20%). The latter are commoner in extranodal DLBCL and in those harboring t(14;18). 38 p53 mutations or deletions are recorded in 20% to 32% of all DLBCLs and are associated with the transformation pathway. They constitute an important adverse prognostic factor along with overexpression of the respective protein 22,106,107 on their own or when combined with miR34A methylation. 108 Dysfunction of p53 may also result from microRNA regulation, CNA of p53, and dysregulation of p53 modulators playing an important role in lymphoma generation and/or progression. 109 Somatic mutations of FOXO1 tumor suppressor, a transcriptional modulator of PI3K signaling, and effector of SYK inhibition are recorded in B9% of DLBCLs and associated with biological aggressiveness. 110, 111 Prognostic Factors in Diffuse Large B-cell Lymphoma, Not Otherwise Specified The IPI, 112 described in 1993, remains the standard tool for prognostication in aggressive lymphomas. It is based on 5 clinical factors, namely age above 60 years, stage III/IV, involvement of Z2 extranodal sites, performance status Z2, and elevated lactate dehydrogenase (LDH), and defines 4 risk groups with 5-year survival rates ranging between 43% to 54% and 84% to 90% under R-CHOP immunochemotherapy. [113] [114] [115] [116] The revised IPI, 114 on the basis of the rearrangement of the number of adverse IPI factors to define new risk groups, and the NCCN-IPI, 116, 117 which further grades age and LDH and takes into account the involvement of specific extranodal sites instead of their number, may be more predictive than IPI, but have not still gained wide acceptance. Many additional prognostic factors have been proposed in the rituximab era aiming to improve IPI and its variants. They can be conventional clinical and laboratory factors, functional imaging (positron emission tomography)-related factors, or biological prognostic factors, including serological markers, DNA polymorphisms, and IHC or molecular markers. Among the latter 2 categories, COO determined by molecular methods or using surrogate IHC classifiers such as the Visco-Young algorithm has clear prognostic relevance as already mentioned. The 2 major prognostic factors-MYC and bcl2-are extensively discussed in other parts of this review. The remaining IHC and molecular prognostic factors, which can be applicable under R-CHOP, will be briefly summarized below. TP53 mutations may add prognostic information independently of COO and MYC + /bcl2 + double-expressor phenotype. 22 Except for the above-analyzed outstanding and reproducible prognostic factors, many other markers have been proposed as determinants of prognosis in DLBCL. An attempt to summarize and classify these markers has been made in Table 4 . Only factors proved to be prognostic under R-CHOP or similar immunochemotherapy using multivariate or stratified survival analysis have been included in this table. Specific disease features, such as CD5 or CD30 positivity, defining immunophenotypic variants are discussed below. 130 Expression of HIF-1a, a master regulator of hypoxia-driven angiogenesis, is associated with favorable prognosis, 141 whereas PD-1/PD-L1 expression, the former with favorable significance, 137 constitute targets for checkpoint inhibitors (nivolumab, pembrolizumab). Increased proliferation rate, as reflected by high Ki67, is associated with inferior outcomes, 139, [148] [149] [150] whereas p21 expression correlates with lower proliferation and better survival. 139, [148] [149] [150] Apart from being the gold standard for the evaluation of COO, GEP studies have revealed other interesting prognostic factors: increased angiogenesis is the hallmark of stromal-2 signature, which has been associated with inferior outcomes 139, [148] [149] [150] ; it can be inferred from increased microvascular density and VEGFR-2 expression. 139, [148] [149] [150] In contrast, SPARC (secreted protein, acidic, and rich in cysteine) expression is indicative of the favorable stromal-1 signature. 151 Molecular prognostic models, for example, LMO2, bcl6, bcl2, FN1, CCND2, and SCYA3, have also been developed, providing IPI-independent prognostic information. 46, 152 Finally, specific miRNAs may provide prognostic information that is independent of the IPI or the above-mentioned 6-gene model. 153 Studies on miRNAs are now accumulating, but are characterized by marked heterogeneity regarding treatment strategies applied and use of multivariate analysis. Thus, miRNA data are still immature. Selected relevant data are provided in Table 4 F vs. UF Associated with GCB; differential effect on outcome independently of COO P-p65 124 UF c-Rel 125 UF Prognostic in all DLBCL and in ABC subgroup independently of myc, bcl2 expression, and TP53 mutations p-AKT 126 UF BAFF-R 127 F Proliferation Ki67 124,128 UF CCND2 118 UF Neoplastic cell surface markers CD5 129, 130 UF Associated with non-GCB; prognostic impact more marked in ABC 88 CD30 22, 27, 131 F Prognostic significance independent of COO and TP53 mutations; different GEP in CD30 + and CD30À MHC class II loss 132 UF CD43 29 UF Associated with non-GCB and obscured COO CD20 loss by flow cytometry 133 UF CXCR4 134, 135 UF Associated with non-GCB, Ki67, myc, bcl2, p53 overexpression; prognostic significance only in GCB independent from myc, bcl2, p53 overexpression and TP53 mutations 144 ; independent of COO 145 SCY3A (MIP-1a or CCL3) 118 UF PD-L1 136 UF Associated with ABC and EBV; obscured the significance of COO Microenvironment PD-1 + TILs 137 F Correlated with GCB and absent PDL-1 in neoplastic cells 136 ; favorable, independently of COO and PDL-1 status CD3 + 138 F SPARC (macros) 139 F Independent of COO; associated with stromal-1 signature extremely rare in the pediatric population. 155 Four morphologic variants have been described by Yamaguchi and colleagues: centroblastic (common 76%), giant cell rich with intravascular involvement (11%), polymorphic (12%), and immunoblastic (1%). Although clinical features do not vary among the 4 variants, the centroblastic morphology portends a more favorable behavior as compared with cases with an intravascular/intrasinusoidal pattern (38%) or giant cell morphology. 154 In the spleen the infiltrate is centered in the red pulp. At the immunophenotypic level there is coexpression of B-cell markers and CD5, in the absence of CD23 and cyclin D1. A subset of cases (25%) with giant cell-rich morphology express CD30. There is a strong association with the non-GCB phenotype (82% of the cases), and bcl2 is expressed more frequently compared with CD5 À DLBCL. 154, 156 Most recently, cyclin D2 was found to be expressed by 98% of these cases but in only 28% of CD5 À DLBCL. 157 Response to standard chemotherapy is inferior to CD5 À DLBCL with frequent relapses, and, although the addition of rituximab has improved the outcomes of CD5 + DLBCL, these remain worse than those of CD5 À cases. Moreover, rituximab has no effect on the CNS relapse rates, thus raising the issue of using CNS prophylaxis. 158 A very recent study reaffirms the adverse prognostic significance of CD5 positivity in DLBCL diagnosed in elderly individuals, irrespective of EBV status. 130 At the genetic level there is a lower rate of ongoing somatic mutations of IgHV genes than in CD5 À DLBCL, a feature indicative of pre-GC derivation (20% of the cases).
Although the vast majority of cases belong to the ABC molecular subgroup sharing the downregulation of extracellular matrix-related genes and the upregulation of TRMP4, they show a distinct molecular signature dominated by SH3BP5 and enriched for neurological functionrelated genes. These findings may provide insight into the propensity of CD5 + DLBCL for CNS relapse. 158, 159 Loss of 9p21 (p16 INK4a locus), gains of 13q21.1-q34 and 13q31-q32, and aberrations of 8p21 may dictate a more aggressive clinical course. 158 A characteristic feature is also the overexpression of integrin b1 by the neoplastic cells and of CD36 by the vascular endothelium. 158 The mechanisms underlying the biological aggressiveness of CD5 DLBCL are not fully understood. In this context, it has been postulated that CD5 may promote the survival of B cells through stimulation of autocrine IL-10 production and may downregulate BCR signaling. 158 Furthermore, the high specificity for cyclin D2, which is known to be controlled by multiple signaling pathways including NF-kB may contribute to the inferior survival of CD5 + DLBCL. 157 CD5 + DLBCL has to be distinguished from secondary CD5 + DLBCL derived from CD5 À DLBCL, CD5 À low-grade B-cell lymphoma and CD5 + follicular lymphoma, primary CNS lymphoma (PCNSL), which may show CD5 expression in 30% of the cases, and IVLBCL. The latter does not express homing molecules such as integrin b1 (CD29) and ICAM (CD54) and has a different clinical presentation with predominantly constitutional symptoms in the absence of a lymph node or extranodal mass. 158 Recently, however, a small series of 8 patients with a hepatosplenic variant of CD5 + DLBCL has been reported. 160 All patients were elderly male individuals presenting with B symptoms, hepatosplenomegaly, and often bone marrow and peripheral blood involvement in the absence of lymphadenopathy or extranodal mass. The spleen and particularly liver and bone marrow showed intrasinusoidal infiltrate by which it overlapped with IVLBCL. This hepatosplenic variant may derive from splenic transitional or prenaive B cells, which may explain the spleen, liver, and peripheral blood tropism. 160 Distinction from paraimmunoblastic variant of chronic lymphocytic leukemia and pleomorphic MCL relies on negative IHC for CD23 and cyclin D1. It should be stressed that because neither morphology nor clinical presentation may predict the presence of CD5 + DLBCL, routine testing for CD5 is recommended in all newly diagnosed DLBCLs for prognostic and therapeutic reasons. between 9.6% to 21% using 20% as the cutoff for CD30 positivity 161 but increases to 25% 27 or even 40% 28 when positivity is defined as >0%. Two large-scale studies, one conducted in the Western population 22 and the other in the ethnically diverse population in British Columbia using different cutoff points for CD30 positivity, agree that CD30 expression is predictive of superior 5-year overall survival (OS) 22 and PFS 22, 27 in R-CHOP-treated patients, independent of IPI. However, in the former study, this favorable effect was independent of COO, 22 whereas in the latter 27 it was elicited only in the GCB group. Interestingly, CD30 expression was strongly associated with EBV infection, 22, 27 and the presence of EBV within CD30 + cases was able to reverse the favorable prognostic effect of the latter, so that coexpression of CD30 and EBER connoted a very aggressive clinical course. 22 Two smaller-scale studies conducted in Chinese 161 and Latin American 26 populations came to the opposite conclusion assigning inferior survival propability to CD30 + cases, which also displayed unfavorable clinicopathologic characteristics. This disparity may reflect ethnical variations but also less strict criteria regarding the absence of immunodeficiency. 26 Importantly, CD30 positivity and MYC aberrations appear to be almost mutually exclusive even in EBV À cases. 22, 27, 28 However, clinicopathologic features were otherwise similar between CD30 À and CD30 + groups. 22, 27, 28 Notably, GEP revealed that the CD30 + group was characterized by the upregulation of negative regulators of NF-kB and the downregulation of BCR signaling genes and genes enhancing cell proliferation as well as prominent cytokine and stromal signatures. 22 From a clinical perspective, these cases are worth recognizing not only for prognostic but also for therapeutic reasons because of the objective response to brentuximab vedotin, which has been observed in 40% of relapsed/refractory cases, even in those with low-level IHC expression. 131 It is, therefore, recommended that all de novo DLBCL cases be routinely tested for CD30 positivity. 162 The favorable prognostic effect of CD30 expression may be related to the activation of cell death signaling or cell cycle arrest as documented in cell lines and mouse models (reviewed in Hu et al 22 ).
CD30 + Diffuse Large B-cell Lymphoma

DIFFUSE LARGE B-CELL LYMPHOMA SUBTYPES AND ENTITIES T-cell/Histiocyte-rich Large B-cell Lymphoma
THRLBCL is a subtype of DLBCL with a prominent component of reactive T cells and histiocytes and a low content of large neoplastic B cells (Figs. 2A-H). 2 Patients are usually middle-aged male individuals (male/female: 1.7/1), although very rare pediatric cases have been most recently recognized. 163 As it has been emphasized, 164 before rendering a diagnosis of THRLBCL in a pediatric population one has first to rule out congenital or acquired immunodeficiencies causing an aberrant immune response or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The typical clinical presentation is that of a predominantly nodal disease at advanced stage with frequent bone marrow, liver, and spleen involvement. Although in an earlier study EBV positivity was seen in 10% of the cases, 165 the WHO classification recommends that EBV + cases be diagnosed as aggressive EBV + DLBCL. 2 The clinical course is aggressive with a 3-year survival rate of 46% and a poor response to chemotherapy. A rare primary cutaneous variant has been reported bearing a more favorable outcome. 166 Cases with THRLBCL features arising from progressed (in a morphologic sense) NLPHL behave less aggressively, even if treated like NLPHL, and appear to be distinct from de novo THRLBCL. 167 Molecular evidence indicating a higher genetic complexity and a higher frequency of BCL6 translocations in NLPHL compared with THRLBCL renders unlikely the progression of NLPHL to THRLBCL. 168 Histologic examination shows a complete effacement of lymph node architecture by a diffusely growing (or vaguely nodular) infiltrate comprising few large neoplastic cells (< 10% of the total lymphoid population), usually singly dispersed or, rarely, forming small clusters amidst small lymphocytes and nonepithelioid histiocytes. As only cases rich in histiocytes behave aggressively, their presence is considered a diagnostic hallmark of this lymphoma. 164 The neoplastic cells have centroblastic/immunoblastic morphology but may be reminiscent of lymphocytic and histiocytic (popcorn) cells of NLPHL or HRS cells. 165, 169 They are positive for pan-B-cell markers, bcl6 (50% to 91%), EMA (B30%), and bcl2 (B40%), rarely positive for CD30 (8% to 30%) but negative for CD10, CD15, and CD138. 167 The background small lymphocytes are overwhelmingly T cells (CD3 + /CD5 + ) predominantly of cytotoxic type (CD8 + / TIA1 + ), with only few CD4 + /CD57 + T cells and a near absence of small B lymphocytes (Figs. 2G, H). The low number of neoplastic cells is thought to result from increased apoptosis mediated by cytotoxic T cells. Follicular dendritic cell (FDCs) meshworks are not seen by immunostaining for CD21, CD23, or CD35, and histiocytes are highlighted by CD68 and CD163 immunostaining. 164 At the genetic level, the presence of hypermutated IGH genes points toward a GC stage of differentiation in the majority of cases. Comparative genomic hybridization (CGH) has identified genomic imbalances in all cases. GEP studies have recently provided evidence in favor of a tolerogenic microenvironment illustrated by a host immune response signature dominated by an IFN-g-dependent pathway. The molecular profile indicates a macrophage/ histiocyte activated status enabling tumor cells to escape immune surveillance and underscores the crucial role of histiocytes in the biological aggressiveness of THRLBCL. 164 IFN-g is responsible for the upregulation of chemokine (E-C motif) ligand 8 (CCL8) and indoleamine 2,3-dioxygenase (IDO) in THRLBCL. The former, being one of the most potent monocyte chemoattractants, may contribute to the histiocyte-rich background of THRLBCL. IFN-g, in synergy with Toll-like receptor ligands, stimulates histiocytes and dendritic cells to produce high levels of IDO, which is known to suppress local T-cell response and, through the conversion of effector T cells into regulatory T cells, ultimately promotes tumoral immune tolerance. 164, 170 Therefore, reserving the diagnosis of THRLBCL for cases with a high content of histiocytes might be therapeutically relevant as modulating the histiocyte activity by IDO inhibition could provide new therapeutic options. 164 GEP of microdissected histiocytes has recently shed light upon their unique features consisting of a biactivated M1/M2 phenotype and expression of metal-binding proteins. The most highly expressed genes by these histiocytes are MT2A member of the metallothionein family, TXN involved in redox reactions, and proinflammatory genes, such as the IFN-g-induced chemokine ligand CXCL9. 171 The most important differential diagnostic consideration from a prognostic and therapeutic perspective is NLPHL with a diffuse pattern. Neither the morphology nor the immunophenotype of the neoplastic cells is definitive in this distinction, although a lack of bcl6 with expression of MUM1 would favor THRLBCL, 168 whereas IgD expression by the neoplastic cells argues strongly in favor of NLPHL. 167 The real clue to this differential diagnosis lies in the different composition of the background population between the 2 entities ( Table 5 ). The presence of more than a few B lymphocytes, either in a diffuse distribution or in nodules rich in FDCs, along with a predominance of CD4 + /CD57 + /PD-1 + T lymphocytes (TFH) cells, supports NLPHL. PD-1 has proved to be particularly useful in the delineation of T-cell rosettes (which is not a feature of THRLBCL) around the lymphocytic and histiocytic cells even in cases of NLPHL with diffuse growth and B-cell depletion. 167 However, the borders between the 2 diseases are apparently not as sharp as it might be thought. First, when Hartman et al 172 enumerated CD4 + and CD8 + cells in NLPHL and THRLBCL tissue sections, CD8 counts did not differ, although CD4 counts were higher in NLPHL. These authors also verified the increased presence of CD163 + histiocytes in THRLBCL over NLPHL. Second, using gene expression analysis of microdissected tumor cells very few differentially expressed genes were identified, for example, strong expression of BAT3/BAG6 in THRLBCL. 172 Third, array CGH revealed similarities among NLPHL, THRLBCL-like variant of NLPHL, and THRLBCL, that is, gains of 2p16.1 affecting the REL locus and losses of 2p19.2 and 9p11.2. 173 On the basis of these data, it seems more appropriate to consider NLPHL and THRLBCL as members of the same pathobiological spectrum, their clinical manifestations being largely dictated by the microenviroment in relation to the immune status of the patient. 172 Following this argument, Treetipsatit et al 174 report a series of 5 cases characterized by large B cells in a T-cell-rich background with CD4/PD-1 + rosetting and nodules without FDCs. Although the immunophenotype and architecture would be more in keeping with NLPHL, the absence of FDCs (according to WHO definition) and the clinical features pointed toward THRLBCL. Therefore, the authors proposed for these cases the term "B-cell lymphoma with features intermediate between NLPHL and THRLBCL." 174 
Primary Mediastinal Large B-cell Lymphoma
PMLBCL is a clinicopathologic entity with distinct histologic, IHC, clinical, and molecular features compared with other aggressive LBCLs (Figs. 2I-P). It accounts for 2.5% of all NHLs and approximately 10% of aggressive LBCLs. 2 It is predominantly a disease of young individuals with a median age between 30 and 35 years, [175] [176] [177] [178] [179] although 5% to 6% of patients are more than 60 years old in most published studies. [176] [177] [178] [179] There is also a female predilection (1.5 to 2:1). [176] [177] [178] [179] Familial aggregation has been described in rare cases. 180 Patients usually present with dry cough, dyspnea, and/or compressive symptoms, such as the superior vena cava syndrome (up to >40% of cases) due to a dominant large mediastinal mass. Marked pleural and pericardial effusions may result in cardiac tamponade. As a result, performance status is poor, that is, Z2 in B30% of the cases, whereas the frequency of systemic B symptoms is B40%. [176] [177] [178] [179] Adjacent involvement of lungs or other intrathoracic extranodal structures is common, typically signifying stage IIE rather than IV. Involvement of supraclavicular and cervical nodes is frequent and nodal disease below the diaphragm can be seen in up to 10% to 12% of patients at diagnosis. In an even smaller minority (< 5%), patients have involvement of uncommon extranodal sites at diagnosis, mainly kidneys, liver, adrenals, GI tract, ovaries, [176] [177] [178] [179] [180] [181] [182] [183] and CNS, [181] [182] [183] although this is much more common at relapse/progression. Bone marrow involvement is almost invariably absent at diagnosis 177, 179, 181 and rarely seen at relapse/progression. 181 Morphology is characterized by compartmentalizing fibrosis and diffuse infiltration by medium-sized or large lymphoid cells embedded in a variably sclerotic stroma. Sclerosing reaction is frequently absent in cervical and supraclavicular lymph nodes outside the dominant mediastinal mass. 181 Variation in cell size and morphology can be prominent among different cases. The neoplastic cells usually have abundant pale cytoplasm resulting in "clear cell morphology," pleomorphic morphology, or multilobated nuclei causing confusion with HL. Necrotic areas can also be present and may be occasionally extensive. Thymic epithelial remnants highlighted with cytokeratin stain are seen in up to 50% of the cases. 181, 184 The neoplastic cells express pan-B-cell markers, such as CD19, CD20, CD22, CD79a, and PAX5, and they typically lack Ig expression in the majority of cases. 2, 181, 185, 186 The expression of HLA class I and/or II molecules is also absent or defective in most cases 2, 181 and may in part explain the absence of serum b2-microglobulin elevations in most PMLBCL patients. 181 CD30 expression is seen in B80% of the cases, indicating a possible future therapeutic target in the era of therapy with brentuximab vedotin. 131 The expression is faint and heterogenous, usually being detected in a proportion (up to 50%) of the neoplastic cells. 186 CD15 expression is almost never seen. 2, 186 The neoplastic cells are usually CD10 À (70% to 90%), bcl6 + (45% of the cases), 2,186 and MUM1 + (B75%). 2, 186 Bcl2 is variably expressed in 50% to 80% of the cases, 2,186 and the majority of cases have a non-GC phenotype. However, this is misleading with respect to the actual COO, as PMLBCL is distinct from either DLBCL subtype. 175 On the basis of the expression of CD23 and MAL (see below), the presence of thymic epithelial remnants within the tumor, and the anatomic localization of the disease, PMLBCL is considered to originate from the adenosine deaminase-positive, asteroid B cells of the thymic medulla. 2, 181 PMLBCL should be differentiated from cHL, DLBCL, and "gray zone" lymphomas with features intermediate between DLBCL and cHL. Mediastinal biopsies obtained under CT guidance may be too small or of poor quality, leading to diagnostic difficulties. Regarding the distinction from cHL a CD20 + /CD15 À /CD45 + immunophenotype is usually discriminative. In addition, galectin-1, c-Jun, and fascin are typical markers of classical HL, and the combined expression of galectin-1 and c-Jun is very unusual in PMLBCL. 187 According to others, Bob.1, CD79a, and cyclin E expression may be the most appropriate markers for this distinction. 188 Comparing PMLBCL with DLBCL, CD23, c-Rel, TRAF-1, MAL, and CD200 are much more frequently expressed in the former compared with the latter. CD23 is expressed in the thymic medullary asteroid B cells, and, consequently, it is positive in 70% to 85% of PMLBCLs versus 4% to 15% of DLBCLs. [189] [190] [191] Given that NF-kB is constitutively activated in PMLBCL, nuclear expression of c-Rel, a member of the NF-kB family, as well as expression of TRAF-1 (TNF receptor-associated factor 1), a target of NF-kB, are observed in 60% to 65% of PMLBCL versus 10% to 20% of DLBCL cases. Moreover, their combined expression is observed in >50% versus only 2% of PMLBCL and DLBCL cases, respectively. 187 MAL, another marker of thymic medullary asteroid B cells, is expressed in 70% versus 3% of PMLBCL and DLBCL, respectively. 190, 192, 193 Finally, the corresponding frequency of CD200 expression was 94% versus 7% in a recent study. 187 Combining all these 5 markers, 37% of PMLBCL cases had score 5, 43% had 4, 11% had 3, and only 3% had a score 2. This distribution was totally different from the one observed in DLBCL. 187 At the genetic level, the neoplastic cells are characterized by the presence of clonal IG gene rearrangements with somatic hypermutation 194 and frequent aberrations (gains or gene amplification) of the 9p and 2p loci. Potential genes involved include JAK2, PDL-1, PDL-2, and JMJD2C 194 and REL and bcl11A, respectively (see below). The gene expression signature of PMLBCL is different from that of DLBCL and resembles cHL. 175 PMLBCL is characterized by constitutive activation of the NF-kB and JAK-STAT pathways and reduced MHC molecule expression. The NF-kB pathway is activated through several mechanisms. Rel, whose product is a part of the NF-kB complex, is involved in 2p aberrations, which are observed in at least 50% of cases of PMLBCL. 195 Furthermore, inactivating mutations of TNFAIP3, resulting in constitutive activation of NF-kB, are found in 1/3 cases. Its product, the A20 protein, causes proteolytic degradation of the IkB kinase complex, thus being a negative regulator of NF-kB. 194 The JAK-STAT pathway is also activated through diverse mechanisms such as genomic gains or amplifications involving 9p24.1 (2/3 cases). 196 45% of cases is another mechanism of constitutive activation of JAK-STAT pathway. 194, 197 Furthermore, 22% of PMLBCL cases bear inactivating mutations of PTPN 198 resulting in increased JAK-STAT protein phosphorylation and constitutive STAT6 activation. In contrast, the pathogenetic significance of STAT6 mutations found in 1/3 of the cases is debated. 199 Finally, loss or reduced MHC II molecule expression is frequent in PMLBCL, correlating with decreased tumoral CD8 + cytotoxic T cells and potential loss of immune surveillance. CIITA, a gene that promotes the expression of MHC II, is inactivated in 38% of PMLBCL cases due to translocations, deletions, or mutations. 200 Another mechanism of escape from immune surveillance through the exhaustion of cytotoxic T cells is related to the overexpression of programmed death ligand 1 kai 2 (PD-L1, PD-L2), due to 9p24.1 aberrations observed in 2/3 cases, 196 9p24.1 genomic rearrangements (20% of cases), 201 or the formation of CIITA/PD-L chimeric genes in cases with CIITA abnormalities. 200 These genetic events may provide targets for therapeutic interventions with nivolumab or pembrolizumab.
Primary Cutaneous Large B-cell Lymphoma
PCLBCL cases account for 6% of all primary cutaneous lymphoma. Overall, they behave more aggressively than primary cutaneous follicle center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma, with a 5year survival rate of 20% to 55% and a tendency for extracutaneous and lymph node spread. They are further classified into "leg-type" and others. 202, 203 Primary Cutaneous Large B-cell Lymphoma, Leg Type PCLBCL usually presents with single or multiple erythematous or violaceous nodules or tumors, often ulcerated, restricted to one anatomic region (Figs. 3A-F). Lesions are typically located on the lower legs of elderly women (male/female: 1/2 to 4), although in 10% to 20% of the cases, other cutaneous sites are affected (reviewed in Hristov 204 ). The presence of multiple lesions (20% of cases) and location on the legs have been identified as poor prognostic factors (reviewed in Lima 202 ). Although, by definition, the lesions are limited to the skin at presentation, they often spread to extracutaneous sites, for example, lymph nodes, bone marrow, and CNS. 204 Half of the patients will die of the disease during 5 years after diagnosis, 205 and, therefore, it is recommended that these lymphomas be treated similarly to systemic DLBCL with R-CHOP and possibly radiation. Despite response to treatment, however, relapses are very common. 202, 204 On histologic examination, there is massive infiltration of dermis and subcutis by large transformed cells with round cell morphology (that is, centroblasts and immunoblasts), which spare the epidermis from which they are separated by a grenz zone. However, in areas of ulceration the infiltrate abuts to the dermo-epidermal junction. Growth pattern is diffuse but compartmentalization by fibrous tissue may impart a multinodular appearance. The neoplastic cells display prominent mitotic and apoptotic activity. In contrast to PCFCL, small lymphocytes are sparse. 204 In addition to pan-B-cell markers, the neoplastic cells typically coexpress bcl2, bcl6, MUM1, and FOXP1. CD10 and CD138 are negative, and there are no meshworks of FDCs. However, this immunophenotype is not specific to PCLBCL, leg type and the possibility of nodal DLBCL secondarily involving the skin has to be excluded, this rendering clinical staging mandatory. 204 It is to be noted that 10% of the cases fail to express bcl2 and/or MUM1. 2 Some experts prefer to classify those bcl2 À PCLBCL cases as "PCLBCL-other" (discussed below) despite the fact that their behavior is similar to PCLBCL, leg type. 203 The identification of IgM and p63 has been reported to facilitate the distinction from PCFCL, the latter type failing to express these 2 markers [206] [207] [208] (Table 6 ). The molecular profile of PCLBCL, leg type is distinct from that of PCFCL and resembles that of the ABC type 202 including NF-kB-activating gene aberrations, such as MYD88 mutations recorded in B70% of the cases. 209 These findings may raise the therapeutic consideration of NF-kB inhibitors. 205 In addition, FISH has revealed translocations involving IGH, MYC, and BCL6 genes. 210 There is overexpression of IgM mRNA and BCL2 amplification but no t (14;18) . Differential diagnosis includes mainly PCFCL with large centrocytes and diffuse growth pattern, which in most cases shows a different immunophenotype ( Table 6 ) and higher numbers of reactive T cells. The group of PCLBCLother includes cases of LBCLs presenting in the skin but not meeting the criteria for PCLBCL, leg type. In particular, PBL, IVLBCL, or THRLBCL are included in this group provided that they are limited to the skin at presentation. These cases tend to pursue a more indolent course compared with their systemic counterpart but are treated similarly to PCLBCL, leg type. 202 In addition, cases of LBCL with anaplastic morphology and CD30 expression, spindle cell or multilobated morphology may also be classified in this group. 204 The differential diagnosis may also include EBV + DLBCL-e, which is more polymorphous with necrosis and diffuse EBER positivity, as well as LYG in which there should also be pulmonary involvement and a mixed infiltrate with many T cells. Finally, the presence of large B cells may suggest the possibility of EBV-associated mucocutaneous ulcer (discussed in the section of EBV + DLBCL-e). This is characterized by a mixed inflammatory background and the expression of CD30, EBER, and often CD15 by the large B cells. 204 
Intravascular Large B-cell Lymphoma (Also Known as Angiotropic Lymphoma or Intravascular Lymphomatosis)
IVLBCL is a very rare type of LBCL affecting extranodal sites in which the neoplastic cells are seen exclusively within small caliber blood vessels (Figs. 3G-I). 2 Patients are usually middle-aged or elderly individuals with a slight male predominance, who most commonly present with fever (45%), cutaneous lesions (39%), and neurological manifestations (34%). Lymph nodes are spared. However, the diagnosis is elusive because nonspecific symptoms related to any other organ dysfunction may be seen. 2 The vast majority of patients are diagnosed with stage III/IV disease. On rare occasions IVLBCL may represent an evolution from another type of lymphoma, for example, nodal DLBCL or MCL. 211, 212 This is an aggressive lymphoma with dismal prognosis largely due to the delay in arriving at the correct diagnosis. 213 Two forms have been described: the classical or Western form with a cutaneous variant, and the Asian or hemophagocytic form diagnosed more frequently in the Far East, Japan, and less often Africa. The former is characterized by a variety of cutaneous manifestations rarely accompanied by bone marrow involvement. In the cutaneous variant the lymphoma is confined to the skin and shows a predilection for young female individuals. In these cases the prognosis is better (3-y survival rate 56%). Cutaneous lesions include purplish patches or plaques and telangiectatic lesions located on the legs and trunk. In some cases the lymphoma arises in preexisting cutaneous angiomatous lesions. 202 The Asian form manifests with multiorgan failure, pancytopenia, hepatosplenomegaly, and hemophagocytic syndrome, whereas cutaneous lesions are rare. Rare cases of IVLBCL with a leukemic component have been reported, 214 and a unique case superimposed on GI stromal tumor has been more recently described. 215 Tissue biopsy should be taken to make a definitive diagnosis if possible from the involved organ. When this is not feasible, random skin biopsies from seemingly unaffected skin (sensitivity 83%) and bone marrow trephine for the Asian form (sensitivity 92% to 96%) are the most rewarding in achieving a definitive diagnosis. 211, 212 Microscopic examination reveals the presence of medium-sized to large-sized lymphoid cells with prominent nucleoli, within capillaries and sinusoids. By definition, extravascular growth should be absent to minimal. On occasion, the neoplastic cells may display Reed-Sternberg morphology. 216 Because of vascular occlusion by the neoplastic cells, ischemia ensues with consequent tissue infarction. Notably, larger arteries or veins are spared. It should be stressed that the intravascular distribution of neoplastic B lymphocytes is not diagnostic of IVLBCL on its own, and, to verify the diagnosis, random biopsies from uninvolved organs should demonstrate IVLBCL. 211 Immunophenotype is usually of non-GCB type (80%). Besides traditional pan-B-cell markers, MUM1 (95%) and bcl2 (91%) are often coexpressed. Notably, CD5 positivity is recorded in 20% to 38% of the cases, whereas CD10, bcl6, or CD30 are rarely recorded 211, 216 (Fig. 3I ). It has been suggested that the Asian variant represents a unique form of the GCB type of CD5 + DLBCL. Accordingly, CD5 negativity may be indicative of the Western variant. 212 Because of CD5 positivity in a subset of IVLBCL cases, the differential diagnosis with CD5 + DLBCL presenting an intravascular/intrasinusoidal growth is raised. The latter, however, frequently displays binucleated tumor cells and also some extravascular neoplastic growth. 211 The mechanisms of the selective intravascular growth of IVLBCL cells are largely unknown. It is postulated that the underexpression of CD29 (integrin b1), CD18 (integrin b2), and CD54 (ICAM-1) by the neoplastic cells, prevents transvascular trafficking, whereas the aberrant expression of CXCR3 by the neoplastic cells and its ligand (CXCL9) by the endothelial cells may sustain the aggregation of the neoplastic cells within the vascular lumen. Thirdly, aberrant expression of CD11a allows the neoplastic cells to be attracted by endothelial cells expressing CD54 resulting in À + CD10 + /À À Bcl6 + /À + /À P63 208 À/ + + /À their sequestration in the lumen and leukopenia. 211, 217 Cytogenetic abnormalities are identified in only 57% of the patients. 212 
Lymphomatoid Granulomatosis
LYG represents an EBV-driven angiocentric and angiodestructive lymphoproliferative disorder (LPD), the clinical course of which is dictated by grade ( Figs. 3J-O) . 2 At present, it remains unclear whether it is a unique disease or part of the spectrum of EBV-associated B-cell LPD. 218 It usually affects adults in the fourth to sixth decade of life with a male predominance. Patients are usually not overtly immunodeficient but have subtle deficits in cellular immunity. 219 However, immunosuppressed patients or those with organ transplantation and autoimmune disease have an increased risk of developing LYG. 220 It is an extranodal disease affecting the lungs (100% of cases) and less commonly CNS (38%), liver (19%), skin (17%), and kidney (15%). 218 Lymph nodes, bone marrow, and spleen are spared at diagnosis but may be rarely involved during progression. 221 Less commonly involved sites are adrenal gland, GI tract, conjunctiva, and nasal cavity. 218 In the lung there are multiple, well-circumscribed, often necrotic nodules usually distributed in the middle and lower lobes of both lungs. On occasion, the nodules may coalesce and involve an entire lobe. 220 The diagnosis of LYG requires the presence of an angiocentric/ angiodestructive polymorphous infiltrate comprising a variable number of CD20 + medium-sized to largesized atypical cells in a background of small T lymphocytes (CD3 + ), plasma cells, and histiocytes. The infiltrate replaces the lung parenchyma. Supportive, but not necessarily found, are necrosis of the cellular infiltrate, EBER positivity, and presence of multiple lung nodules or skin/CNS involvement. 222, 223 A lymphoma composed of a uniform population of large EBV + B cells is beyond the spectrum of LYG. 223 EBER negativity is acceptable in grade I LYG provided that the clinical setting and mandatory criteria are present. 223 In the lung the infiltrate shows a patchy distribution, the surrounding parenchyma being unremarkable. 218 Vascular involvement is due to small lymphocytes and when it is extensive results in infarct-like (coagulative) necrosis. The large atypical cells may have immunoblastic or pleomorphic appearance but in grade III they may resemble Hodgkin cells. However, typical binucleated RS cells are not present. 221 Notably, granulomas, eosinophils, or neutrophils are not seen. 218 The skin lesions may be plaques, papules, or nodules and microscopically show features of lobular panniculitis and non-necrotizing granulomatous inflammation. Prominent vascular involvement causes extensive necrosis. In 10% of the cases, skin involvement antedates lung involvement, and in such cases the diagnosis may be challenging. 219 Cutaneous lesions are rarely EBER positive (23% of the cases in the study of Song et al 218 ) and, therefore, are considered inappropriate for grading. 224 The large B cells express pan-B-cell markers, variably CD30 (47% in the study of Song et al 218 ) but are negative for CD15. 220 Light chain restriction has been recorded in 38% of the cases. 218 Small T lymphocytes are predominantly CD4 + with increased numbers of FOXP3 + Tregs in grade III. Grade is defined by the number of EBV + B cells as follows: in grade I <5 EBER + cells/HPF; in grade II, 5 to 20 or 50 EBER + cells/HPF, and in grade III >50 EBER + cells/HPF are seen. EBER-positive cells vary in size and in a large subset of cases coexpress LMP-1 indicative of latency II profile. EBNA-2 positivity (consistent with latency type III) is rare. 220 Grading should be performed in lung biopsies. 218 Grade I accounts for 30% of LYG cases, grade II for 22%, and grade III for 48% of cases. 218 Coagulative necrosis is seen in all grades, but in grade I it may be minimal to absent. 218, 220 Overall, 50% of grade I cases are negative for EBV by EBER and/or LMP-1 IHC. 218 As EBER is negative in necrotic areas, it may not be representative of the total number of atypical B cells, and, therefore, enumeration of CD20 + large cells may be more reliable. 220, 222 Variation of grade within the same biopsy may be seen with grade I usually occupying the periphery of the lesion. Therefore, adequate sampling is mandatory. In concurrent biopsies taken from different sites there is usually no variation in grade. However, in subsequent biopsies there may be a progression or, less often, a decline in grade. 218 Clonality analysis documents IGH rearrangements in 8% of grade I, 50% of grade II, and 69% of grade III cases, whereas a small subset (6%) of grade III cases also harbor clonal T-cell populations. 218 Katzenstein et al 222 have recommended a change in terminology for LYG grade II, being referred to as THRLBCL, EBV + (or less often À), and for LYG grade III, being referred to as DLBCL, EBV + (or less often À).
LYG grades I and II pursue an indolent course with a PFS of 56%, whereas LYG grade III is an aggressive disease, equivalent to DLBCL with a PFS of 44%. 221 It has been postulated that LYG progresses from a grade I polyclonal and immune-dependent disease through a grade II oligoclonal but still immune-dependent phase, to a grade III monoclonal and immune-independent phase. 219 Grade I or II LYG cases are treated with IFN-a, whereas grade III with aggressive chemotherapy (R-CHOP or DA-EPOCH-R). 221 The pathogenesis involves a defective immune surveillance of EBV-infected B cells particularly by the CD8 + T cells, 219 whereas the increased presence of Tregs may contribute to progression suppressing immune surveillance for EBV. 218 The differential diagnosis includes cHL, T/NK-cell lymphomas, and EBV + DLBCL-e. cHL is distinguished by the immunophenotype of HRS cells, that is, CD20 usually À/CD30 + /CD15 + (À). Extranodal NK/T-cell lymphoma displays a cytotoxic phenotype and karyorhectic necrosis, whereas peripheral T-cell lymphoma or ALCL are EBV negative and do not show angiocentricity. EBV + DLBCL-e may affect the lung, and the infiltrate is angiocentric but not angiodestructive. More importantly, there is a diffuse obliteration of the lung architecture by an infiltrate comprising many large B cells and usually fewer small T lymphocytes than LYG. Finally, Pina-Oviedo et al 220 advise to avoid diagnosing LYG in immunodeficient or methotrexate-treated patients.
LARGE B-CELL LYMPHOMAS WITH DEREGULATED IMMUNE SURVEILLANCE BUT WITHOUT OVERT IMMUNODEFICIENCY
This group includes DLBCL associated with chronic inflammation (DLBCL-CI), a distinct clinicopathologic entity, and 2 subtypes, that is, EBV + DLBCL-e and primary DLBCL of the CNS.
Diffuse Large B-cell Lymphoma Associated With Chronic Inflammation
DLBCL-CI is defined in the WHO classification 2 as an EBV-associated aggressive LBCL arising in the context of long-standing chronic inflammation. The prototype is PAL because most originally reported cases developed after artificial pneumothorax treatment for tuberculous pyothorax in Japan. 225 Subsequently, DLBCL-CI has also been described in the setting of chronic osteomyelitis, chronic skin ulcer, around metallic implants in bones and joints, as well as around cardiac myxoma, nonmyxomatous cardiac lesions, and cardiac prostheses (reviewed in Valli et al 226 ) . It is mostly diagnosed in elderly patients (seventh to eighth decade of life) and shows a striking male predominance (male/female: 12/3). In most cases of PAL, pyothorax has been present for >20 years. Recently, a case of "acute-onset" PAL with inflammatory features has been reported by Terada. 227 Notably, EBV À DLBCL arising around chronically inflamed joints in rheumatoid arthritis is not included in this histologic type. Patients with PAL present with a chest wall mass, often large, which may extend to the lung, ribs, diaphragm, or mediastinum. Most patients are diagnosed with low-stage disease.
Microscopy (Figs. 4A-F) shows a conventional DLBCL often with immunoblastic features 228 displaying a B-cell phenotype. However, cases with plasmacytic differentiation may also be seen in which there is a downregulation of CD20/PAX5 and expression of CD138. The adjacent pleura shows fibrous thickening with rather few chronic inflammatory cells. The immunophenotype is usually of the non-GC type. CD30 is variably expressed but EBER, LMP-1, and EBNA-2 are almost constantly positive, reflecting EBV latency type III. 225, 229, 230 PAL is one of the histologic types of B-cell lymphomas often characterized by aberrant expression of T-cell markers (CD2, CD3, CD5, CD7). 15, 229 At the genetic level, PAL was recently reported to harbor p53 mutations (70% of the cases) and MYC chromosomal gains or amplification (80% of the cases), whereas almost one third of the cases showed A20 (TNFAIP3) deletion. 231 GEP has indicated that PAL is distinct from nodal DLBCL displaying an ABC signature. 232 DLBCL-CI is an aggressive disease with a 5-year survival rate of only 22%. 225 The normal cell counterpart is an EBV + transformed B cell in late GC or post-GC stage of differentiation, which is allowed to proliferate and undergo malignant transformation within a local immunodeficiency cytokine-rich microenvironment. 233 Most recently, the spectrum of DLBCL-CI has been expanded by a few reports describing the growth of lymphomatous cells within a cystic lesion such as a renal, adrenal, or splenic cyst, paratesticular hydrocele, and ovarian cystic teratoma. 226, [234] [235] [236] Remarkably, the cells infiltrated the inflamed and often sclerotic cyst wall but did not form a solid mass, and in some cases their presence was an incidental finding. 234 Although morphology and immunophenotype were identical to DLBCL-CI, these "cystic" cases showed a very indolent behavior (reviewed in Valli et al 226 ), on the basis of which it is debatable whether they should be designated cystic DLBCL-CI or considered a distinct variant in order not to be overtreated.
EBV + Diffuse Large B-cell Lymphoma of the Elderly
EBV + DLBCL-e is a provisional term coined by the 2008 WHO classification to describe an EBV + clonal large B-cell proliferation arising in immunocompetent patients over 50 years of age without a prior history of lymphoma. Cases of LYG grade 3 are excluded. 237 The disease belongs to the spectrum of age-related EBV + LPD described by Dojcinov et al 238 and considered to be caused by the senescence of the immune system particularly with regard to adaptive immunity. Normal aging process is responsible for the accumulation of clonal B cells and the reduction of CD4 + and CD8 + cell counts, a progressive decline of the naive T-cell repertoire paralleled by a decline in T-cell receptor diversity, and a progressive expansion of oligoclonal CD28 À T cells. 237 Indeed, T-cell clonal populations have been identified in a subset of these cases. 239 This may be related to the impaired EBV-specific immune responses associated primarily with low numbers of central and effector memory CD8 + T lymphocytes recently reported in EBV + DLBCL-e. 240 Although the actual prevalence of EBV + DLBCL in "elderly" populations is challenged by the absence of uniform cutoff criteria for EBER positivity (> 20% to >90%) and the fact that some reports have excluded patients between 40 and 50 years of age, whereas others did not, recent update in our knowledge concerning this entity strengthens earlier claims about geographical and ethnical variations. Thus, the reported incidence is much higher in Asian/Latin countries (8.9% to 14.9%) compared with Western countries (< 5%). 241 Both nodal and extranodal sites are affected.
Two morphologic subtypes are recognized by the WHO classification: the polymorphic and the monomorphic. The former shows a variety of large neoplastic B cells admixed with variable numbers of reactive cells and has been subdivided by Montes-Moreno et al 239 
into 3 subgroups on the basis of the relative proportion of large neoplastic cells and the presence of HRS-like cells: (a) canonical DLBCL with only scattered HRS-like cells; (b) DLBCL with HL-like features and a low density of HRSlike cells; and (c) DLBCL with polymorphic LPD-like features and a low density of non-HRS-like cells.
The monomorphic subtype is composed of monotonous sheets of large B cells. Both subtypes commonly display areas of geographic necrosis. This distinction, however, has no clinical or prognostic bearing. The immunophenotype is characterized by positivity for pan-B-cell markers, bcl2, and variably CD30. Compared with EBV À DLBCL, EBV + DLBCL has been shown by a matched case-control analysis to be more often of non-GC type (87.5%) and CD30 positive (93.8%). 242 Interestingly, CD30 positivity is much more common in Asian/Latin cases (75% to 89%) than in Western countries (42.3%). 241 CD15 is negative, whereas bcl6 expression is less frequent. 243 EBER is positive in all cases usually in >50% of the neoplastic cells with a latency type II pattern in both Asian and Western cases. 241 This is illustrated by the expression of LMP-1 in >90% of the cases, whereas EBNA-2 positivity (indicative of a latency type III) is distinctly uncommon (26%) and implies an inferior survival in European cases. 244 At the genetic level, this lymphoma belongs usually to the ABC molecular subgroup and is characterized by prominent NF-kB and JAK/STAT signaling activation 239, 241 and few mutations affecting CD79B and CARD11. 245 A20 (TNFAIP3) deletion has been recorded in 13% of cases 231 and no translocations of BCL2, BCL6, MYC, or MYD88 have been detected. 237, 245 Such findings point toward EBV-mediated activation of NF-kB as an alternative to pathologically enforced BCR signaling in EBV + DLBCL-e. 245 In addition, GEP has revealed host immune response as a key molecular signature in EBV + DLBCL-e with gains at 9p24 (PD-L2) promoting immune evasion and sustaining the biological aggressiveness of these cases. 246 Compared with EBV À DLBCL, EBV + DLBCL-e shows significant upregulation of hsa-miR-126, hsa-miR-146a, has-miR-146b, hsa-miR-150, and hsa-miR-222 and downregulation of hsa-miR-151. 247 The notion that EBV infection in DLBCL adversely impacts survival has been consistently reproduced only among Asian/Latin populations, 130, 142, 218, 241, 248, 249 whereas in white populations such an effect has not been substantiated. 243, 250 The median survival for EBV + DLBCL cases in non-white patients is 9 months 218 even in the rituximab era 248 with a 3-year PFS and OS of only 25%. 218 Intriguingly, the largest study conducted in Western populations 250 concluded that CD30 coexpression in EBV + DLBCL cases harbored a distinct molecular signature and connoted a very aggressive behavior compared with CD30 À EBV + cases. The authors did not find any association with clinicopathologic features in contrast to a study in the Korean population 126 in which EBV positivity was associated with involvement of at least 2 extranodal sites, high IPI, and advanced stage. Although the origin of these geographical and ethnical differences in the prognostic impact of EBV positivity remains to be fully elucidated, this may relate to the considerably higher incidence of CD30 positivity in EBV + DLBCL-e in Eastern as opposed to Western populations. 243 Further investigation is warranted to delineate the role of CD30 in EBV + DLBCLe, but, obviously, such findings may provide the rationale for anti-CD30 targeted therapy. 241, 243, 250 Beltran et al 251 were the first to report that EBV + DLBCL is not a disease only of the "elderly," as similar cases may also be encountered in adults below 50 years of age and even in children. 126, 142, 243, [252] [253] [254] Although those cases occurring in the young age group are mainly nodal rather than extranodal, 253 ,254 there appears to be no major difference with regard to clinicopathologic, immunophenotypic, or genetic features, GEP, and microRNA profiling. 243, 254 The incidence in the young age group appears to be lower than in the elderly group, particularly in white populations 243 in whom almost one third of EBV + DLBCL cases are diagnosed in patients below 50 years of age. However, in Korea and Argentina, the reported frequencies among DLBCL cases are 6.7% (vs. 9.3%) 249 and 13% (vs. 8%) 252 for the young (vs. the elderly) groups, respectively. Nicolae and Pittaluga 253 underlie some other differences with regard to the EBV latency profile, which is predominantly of type II, and histology, which is THRLBCL like in 78% of their cases. In pediatric cases from Iraq, an NLPHL-like pattern is prevalent. 254 An interesting feature is the consistent expression of PD-L1 by the neoplastic cells and of IDO by the microenvironment (macrophages), which contributes to dysregulation of immune checkpoints and tumor immune escape, indicative of a tolerogenic immune environment 253 modulated by EBV. The identification of these "young" EBV + DLBCL cases have led many authors to propose modification or even removal of the age criterion from the definition of EBV + DLBCL. 142, 243, 252, 255 Apart from the definitional issues, these observations highlight the concept that immunosenescence or immunosuppression is not a sine qua non for EBV + DLBCL pathogenesis. 241 In this context, EBV-driven lymphomagenesis is mostly attributed to the oncogenic properties of LMP-1, which interacts with several downstream molecules enhancing cell cycle progression, counteracting apoptosis, and activating NFkB, MAPK/ ERK, JAK/STAT, and PI3K/AKT, ultimately increasing cell proliferation. In addition, EBV-encoded viral miRNAs may target p53 function, BCR signaling, oxidative stress response, or apoptosis, facilitate immune evasion, and maintain viral latency. 221 This information may pave the way to novel targeted therapeutic considerations in EBV DLBCL, for example, JAK/STAT, PI3K/AKT, or NF-kB inhibitors. 241 The biological behavior of "EBV + DLBCL of the young" is a controversial issue. Hong et al 249 and Nicolae and Pittaluga 253 report a more favorable prognosis but Ok et al 243 and Lu et al 142 have disputed this finding. The reasons for this disparity are not known but cannot be explained by geographical/ethnical variations.
An important differential diagnostic consideration is EBV + mucocutaneous ulcer 256 associated with age-related immunosenescence or drug-induced immunosuppression. This is a disorder with excellent prognosis, as none of the reported patients died of the disease irrespective of the treatment. Patients present with isolated well-demarkated ulcers in the oropharyngeal mucosa, skin, and GI tract. Microscopy shows a polymorphous infiltrate comprising lymphocytes, plasma cells, histiocytes, and large cells with immunoblastic or HRS features. The infiltrate may be associated with angioinvasion. The large cells express pan-B-cell markers, CD30, and often CD15 and LMP-1. EBER is positive not only in HRS-like cells but also in smaller lymphoid cells. The lymphocytes are of T-cell origin, predominantly CD4 + . Clonality may be misleading if used for the differential diagnosis because 40% of the cases show clonal IGH rearrangements (reviewed in Ok et al 221 ).
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System
Primary DLBCL of the CNS is defined as a DLBCL primarily arising in the brain, spinal cord, meninges, or the eyeball, in the absence of concurrent or prior lymphoma outside the CNS (Figs. 4G-L). 2 Although it may be encountered in 2 clinical settings, that is, immunocompetent elderly adults and immunosuppressed, often HIV + , young male individuals, the term is restricted to cases arising in immunocompetent patients. 257 Exclusion criteria are also the dural involvement and the IVLBCL involving CNS. Although several lymphoma types may exclusively manifest in the CNS, the term primary CNS lymphoma (PCNSL) is synonymous with primary DLBCL of the CNS. 258 When DLBCL involves the optic nerve or the eyeball, it is termed primary intraocular (vitreoretinal) lymphoma. It is worthy of note that 15% to 25% of PCNSL patients develop vitreoretinal involvement and 56% to 90% of primary intraocular lymphoma cases have synchronous or metachronous brain involvement. 259 PCNSL accounts for 4% of intracranial neoplasms and 4% to 6% of extranodal lymphomas (reviewed in Deckert et al 258 ) . Patients present with a single mass (60% of the cases) or multiple lesions, usually in the hemispheres (48%). Other preferential locations are the basal ganglia and the periventricular area (reviewed in Deckert et al 258 ) . Male individuals are more commonly affected than female individuals. Rarely, patients may relapse at extra-CNS sites. Compared with systemic DLBCL, PCNSL carries a poor prognosis, even after initial response to methotrexate, which may be location specific or reflect the paucity of infiltrating immune cells and/or inherent aggressiveness. 260, 261 Microscopy shows a highly cellular patternless tumor, diffusely growing and infiltrating perivascular spaces and cerebral vessel wall. This perivascular pattern is usually evident at the periphery of the tumor and attests to primary rather than to secondary involvement of the CNS by DLBCL. Gill et al 260 noted this pattern in 20% of their PCNSL cases in which an association with shorter PFS was documented. The neoplastic cells have the morphology of centroblasts or less often immunoblasts 258 and are admixed with reactive bystander infiltrates including T and B lymphocytes, macrophages, microglial cells, and astrocytes. In particular, reactive perivascular T cells are seen in 36% of the cases, are usually of cytotoxic, but less often of TFH, type, 258 and confer a more favorable prognosis in patients treated with methotrexate. 262 Lymphomatosis cerebri corresponds to widespread diffuse white matter involvement by lymphoma cells without formation of a discrete mass. This histologic pattern yields a very characteristic imaging appearance of diffuse leucoencephalopathy in both hemispheres without postcontrast enhancement (reviewed in Giannini et al 259 ) .
The neoplastic cells express the pan-B-cell markers but are negative for plasma cell markers CD38 and CD138. The expression of IgM and IgD but not IgG on tumor cells is consistent with an absence of Ig class switch. The combined bcl6 and MUM1 expression (the former often focally, the latter diffusely positive) denote a GC exit stage of maturation, in line with GEP data. 258 Bcl2 is commonly positive (56% to 92%) but this is not due to an underlying t(14;18) 260 (Fig. 4J ). CD10 positivity is seen in only 10% of the cases and serves in the distinction from systemic DLBCL. 259 According to the Hans algorithm, 69% of the cases are of non-GCB type, which is also associated with a higher incidence of bcl2 positivity, and 31% are of the GCB type, 260 although this is not prognostically relevant. Ki67 index is >70% or even 90%. Unfortunately, application of IHC classifiers based on nodal DLBCL has not been successful in PCNSL, which appears to be segregated over the entire genetic spectrum of DLBCL. 263 The presence of 6p21 loss assessed by CGH and BCL6 translocations are of diagnostic value, whereas 6q22 del adversely impacts on prognosis. 264 However, BCL6 translocations are not prognostically informative. 265 Assessment of B-cell clonality may be helpful to establish the diagnosis in the presence of a limited number of neoplastic B cells, particularly after the administration of corticosteroids. However, the higher mutation frequency within the BCR-encoding gene compared with systemic DLBCL limits its usefulness and may lead to false-negative results. 258 There appears to be a link between PCNSL and testicular DLBCL, inasmuch as they both show decreased or absent HLA class I/II molecules allowing the neoplastic cells to survive at immune privileged sites. 266 This liaison is also reflected in the genomic instability and near-uniform biallelic loss of CDKN2A with rare p53 mutations and frequent PD-L1/PD-L2 CNAs in these 2 types of DLBCL. 267 Recent research has identified a very high frequency of NF-kB gene network mutations most commonly affecting CD79B (83%), MYD88 (36% to 76%), TBL1XR1 (23%), PRDM1 (20%), and CREBBP1 (20%), often simultaneously. Thus, diverse pathways within this network seem to be affected. [268] [269] [270] The much higher prevalence of CD79B/MYD88 mutations compared with systemic DLBCL probably reflects the paucity of antigenic stimuli from the immune system within CNS necessitating the substitution by constitutive activation of CD79B/MYD88 to initiate the signaling cascade. 270 MYD88 mutation has recently been highlighted as a fairly consistent genetic feature also in testicular DLBCL. 271 These hotspot mutations serve as a genetic hallmark for PCNSL of diagnostic and prognostic value. 272 The tropism of PCNSL for CNS may be partly explained by the recently identified affinity of PCNSL BCRs for CNS proteins, which are recognized as self-antigens further contributing to BCR signaling. 273 The incidence of MYC translocations appears to be lower than in systemic DLBCL, 260, 265, 274 and increased MYC copy numbers have been documented in 27% of the cases. 260 However, MYC overexpression appears to be more common (73%), and in 60% of the cases it is accompanied by bcl2 overexpression. 260 Thus, in PCNSL MYC overexpression appears to be independent of MYC aberrations and possibly results from NF-kB or BCR signaling activation 260 as well as from posttranscriptional or posttranslational upregulation. 274 MYC overexpression is reported by Tapia et al 265 as an adverse prognosticator; however, this finding is disputed by others. 260 The prevalence of EBV in immunocompetent patients with PCNSL ranges between 0% and 20% (reviewed in Giannini et al 259 ). This variation probably reflects geographical differences. 275 EBV displays a latency type III profile 276 and confers a poorer prognosis. 277, 278 These cases present with an angiocentric and angiodestructive growth resulting in extensive necrosis and are characterized by a very high number of reactive T cells, so that the histology may be reminiscent of LYG. Giannini et al 259 have emphasized the diagnostic utility of CD20 to reveal the large neoplastic B cells even in cases with extensive necrosis.
EBV + Primary Central Nervous System Lymphoma of the Elderly
EBV + PCNSL of the elderly represents 4% of PCNSL in Japan, 275 but its incidence in Western countries is unknown. Jamal et al 275 reported 5 such cases occurring in immunocompetent patients over 65 years of age and carrying an unfavorable prognosis. They differed from the respective systemic DLBCL by displaying a monomorphous appearance, less prominent angiocentric pattern, and variable necrosis. The presence of the latter in PCNSL should raise the suspicion of EBV infection. All cases were bcl2 positive, but MYC overexpression was distinctly uncommon (1/5 cases), as opposed to EBV À PCNSL, whereas MYC translocations were not detected. Furthermore, clonal T-cell populations were detected in 2/5 cases. 239, 275 Corticosteroid-induced effects on PCNSL (so-called corticosteroid-mitigated PCNSL) include apoptosis-related changes characterized by rapid vanishing of the tumor cells, large numbers of foamy macrophages containing cellular debris, astrocytic gliosis, and predominantly T-cell inflammatory infiltrate. The latter displays prominent proliferative activity (Ki67 index 20% to 50%) reflecting its activation status thus raising the differential diagnosis with T-cell lymphoma or histiocytic disorder. Molecular analysis may be helpful in identifying BCR rearrangement while failing to reveal T-cell clonal population. However, in cases with complete depletion of neoplastic B cells, even those techniques may yield negative results. 258 
LARGE B-CELL LYMPHOMAS WITH PLASMABLASTIC FEATURES
This is a heterogenous group of (very) aggressive lymphomas originating from terminally differentiated B cells with overlapping morphologic and immunophenotypic characteristics but discrete clinical and molecular features. According to 2008 WHO 2 classification, 4 histologic types are recognized: PBL, PEL, LBCL arising in the setting of HHV-8/KSHV + multicentric Castleman disease (MCD), and ALK + LBCL. However, in recent years, cases of EBV + DLBCL-e as well as DLBCL, NOS with plasmablastic features have also been described. 7, 279 Most of these cases arise in the setting of immunodeficiency usually as a result of HIV infection. It is thought that HIV mediates dysregulation of the immune responses controlling EBV and HHV-8. 280 It is, therefore, not surprising that LBCLs with plasmablastic differentiation arising in HIV + patients are EBV and/or, less commonly, HHV-8 positive. 281 The normal cell counterpart for this group of lymphomas is considered to be the plasmablast, which is a B cell with immunoblastic morphology undergoing preterminal differentiation to plasma cell. This translates to the gradual overexpression of transcription factors essential for full plasma cell development plus downregulation of B-cell lineage transcription factors. Plasmablasts may originate either from a naive unmutated IgMl-producing B cell or from a class-switched and hypermutated post-GC B cell, which explains the significant heterogeneity at the mutational level among the specific types of LBCLs with plasmablastic features. Such genetic differences do not appear to have a clinical impact as in other cases of B-cell lymphomas. Plasmablasts are rare in normal lymphoid tissue but become evident when clonally expanded as a result of viral infection. These plasmablastic expansions are also encountered in other LPDs, such as HHV-8 + MCD and EBV-associated germinotropic LPD. 282 Three criteria have to be satisfied for plasmablastic differentiation to be identified: immunoblastic/plasmablastic morphology, a high proliferation rate, and a phenotype denoting plasma cell differentiation. The latter is defined not only by the gradual overexpression of plasma cell transcription factors, such as PRDM1/Blimp1, MUM1/IRF4, and XBP1s, but also by the extinction of the B-cell differentiation program. Thus, CD20 and PAX5 are negative or weakly positive, whereas CD38, CD138, and often CD56 are positive. 282 For this reason, this group of lymphomas is referred to in recent literature as "CD20negative DLBCL." 283, 284 With the use of a growing panel of markers, it has become evident that the terminal differentiation of neoplastic B cells is a gradual process with at least 2 phenotypes having been observed: a full plasmablastic phenotype (PRDM1/Blimp1 + /XBP1s + /CD20 and PAX5 -or weakly +) and a variant (faulty) plasmablastic phenotype (< 2 plasma cell markers positive, PRDM1/Blimp1 and XBP1s + /À , CD138 À/ +). 285 These characteristic phenotypes are highly unusual in conventional DLBCLs of ABC type. 285 Given that PRDM1/Blimp1 is the driver of plasmablastic phenotype and its expression is abrogated in 50% of DLBCLs-ABC type due to various mechanisms (homozygous deletions, truncating or missense mutations, and transcriptional repression by BCL6), it is advanced as the preferred diagnostic marker for plasmablastic differentiation always in combination with the downregulation of B-cell markers. 282 A partial plasmablastic phenotype defined by the expression of PRDM1/Blimp1 in 30% to 40% of CD20 + DLBCLs reportedly connotes a shorter survival in both nodal 285 and gastric cases. 286 This obviously expands the spectrum of plasmablastic differentiation to a subset of DLBCLs-ABC type. At the other end of the spectrum there is plasmablastic myeloma (PBM) sharing an identical immunophenotype with PBL but displaying distinctive clinicopathologic features. However, cases overlapping with both PBL and PBM do exist and underlie the concept of plasmablastic differentiation as a continuum. 287 Plasmablastic Lymphoma PBL was originally described as an aggressive LBCL with immunoblastic morphology, a plasma cell immunophenotype, and a striking propensity for the oral cavity of HIV + patients. 288 Subsequent reports, however, highlight the involvement of extraoral sites in >60% of the cases, of which GI tract is the most common. 284, 289 Extranodal sites are much more commonly affected than lymph nodes, 238, 284, 290 and there is a striking male predominance. 284 Rarely, PBL may present as a primary cutaneous lymphoma. 291 Furthermore, up to 50% of the patients are HIV negative, 238, 290 almost one third of whom have iatrogenic immunosuppression, but the remaining (14% to 20%) are immunocompetent. 238, 289, 290, 292 HIV + patients have on average of <200 mm 3 CD4 + T lymphocytes in the peripheral blood. 238 An occasional case of PBL has been reported in a patient with Crohn colitis and hepatitis C. 293 PBL accounts for 3% of NHLs arising in HIV + patients but otherwise is uncommon. HIV + cases are associated with younger age and a more frequent oral presentation. 238, 290 B symptoms and bone marrow involvement are often present at diagnosis irrespective of the HIV status. Interestingly, there is a bimodal distribution of stage in HIV + patients with >80% of them being diagnosed with stage I (32%) or IV (49%). 289 Morphologically, HIV + and HIV À cases show a spectrum ranging from centroblastic/immunoblastic to purely plasmablastic verified by the presence of a paranuclear hof. However, many cases are polymorphic, comprising immunoblasts, plasmablasts, and plasma cells. 279 The oral cases arising in HIV + patients commonly display plasmablastic morphology (Figs. 5A-F), whereas extraoral cases in HIV À patients appear more plasmacytic 292 (Figs. 5G-L) .
The phenotypic profile is usually (57%) fully plasmablastic. 279, 285 Thus, the neoplastic cells are largely negative for CD20 and PAX5 while expressing plasma cell markers (CD38VS, CD138, MUM1/IRF4, EMA, PRDM1/Blimp1, XBP1s). Antigens variably expressed are CD45 (most often in posttransplant cases), 290 CD79a, CD43, CD30 (80%), CD56 (particularly in extraoral cases), 291 CD10 (particularly in posttransplant cases 290 ), and monotypic cIg usually of IgG type. CD20 and CD56 positivity have been more frequently recorded in HIV + cases. 289 Aberrant expression of T-cell markers, such as CD3, may be seen. 15, 279 CD45 positivity and a Ki67 index Z80% have been reported as adverse prognosticators. 238, 290 The infrequent expression of GC markers such as bcl6 or GCET1 by PBL argues in favor of an origin from B cells that have experienced the GC reaction as evidenced by IGH somatic hypermutation. However, some cases in the HIV setting may originate from naive B cells undergoing preterminal differentiation. 279, 282 The presence of EBVencoded RNA within tumor cells as assessed by in situ hybridization (EBER) is seen in the majority (50% to 75%) of cases, especially those arising in HIV + patients 238, 289, 290 with a type I latency pattern. EBV is largely responsible for the downregulation of transcriptional B-cell program through PAX5 promoter methylation and the promotion of plasmablastic phenotype through endoplasmic reticulum stress-mediated XBP1s activation and nuclear accumulation. 284 Nevertheless, EBV positivity has been recently brought forward as a favorable prognosticator perhaps through triggering of a more effective antitumor immune response. 238, 290 A significantly higher prevalence of EBV has been noted in oral cases. 292 Given the differences with regard to morphology, HIV status, and EBV status, Hansra et al 292 were led to the assumption that PBL represents a heterogenous disease with 2 distinct subtypes: oral and extraoral.
The genomic profile is closer to DLBCL-ABC type, 294 although, occasionally, complex cytogenetic abnormalities of myeloma type have been reported. 287 IGH/MYC translocations are documented in B50% of the cases, often in the context of complex karyotypes 295 and associated with EBV infection. 296 Besides MYC translocations, MYC gains have also been frequently recorded in PBL, so that the overall incidence of MYC aberrations (translocations/ chromosomal gains) rises to 62.5%. 238 There is a significant association of MYC aberrations with HIV positivity (78%) 290 and with a poorer survival. 238, 290 Recently, gene expression analysis has revealed upregulation of DNMT3B, PTP4A3, and CD320 in EBV + , posttransplant PBL cases highlighting the heterogeneity of pathogenetic mechanisms of PBL operating in different immunologic settings. 290 The biological explanation for the poor response of PBL to current therapies including R-CHOP might be related to the partial or complete loss of CD20 297, 298 as well as to loss of MHC class II expression, secondary to downregulation of CIITA by PRDM1/Blimp1. 285 Furthermore, the induction of the terminal differentiation program characterized by the nuclear accumulation of XBP1s may provide the rationale for new therapeutic considerations in PBL, such as proteasome inhibitors that destabilize the unfolded protein response. 299 The addition of HAART in HIV + cases may improve host immunodeficiency and increase survival rate. 238 PBL represents not only a therapeutic but also a diagnostic challenge. 300 The differential diagnosis from Bcell and T-cell neoplasms is summarized in Table 7 . However, the main differential diagnostic consideration is the plasmablastic variant of plasma cell myeloma (PBM) due to the considerable morphologic and immunophenotypic similarities. At present, this differential diagnosis is mandatory because of different therapy. PBM is encountered in the setting of progression of a plasma cell myeloma, usually in extranodal sites. Its molecular features appear closer to PBL than to plasma cell myeloma with a 50% incidence of MYC translocations. As shown in Table 8 , the presence of serum paraprotein, bone lesions, and a clinical history of myeloma along with a negative EBER and Ki67 < 60% are more in keeping with the diagnosis of PBM. [301] [302] [303] [304] Recently, however, cases with plasmablastic morphology and overlapping clinical and molecular features with PBL and PBM have been reported speaking in favor of a biological liaison between the 2 entities, the denominator of which is the dysregulation of MYC. 287, [305] [306] [307] [308] Plasmablastic transformation of a preexisting lowgrade B-cell lymphoma is a rare occurrence. Martinez et al 309 have reported 6 cases, 3 of which involved extranodal sites. However, there are some differences compared with de novo PBL. There was no association with immunodeficiency, and IGH/MYC translocations were documented in only 2/6 cases. EBER was rarely positive, and the plasmablastic component was usually clonally related to the underlying low-grade lymphoma.
Plasmablastic Lymphoma of the Elderly
A variant of PBL has been recently described in HIV À elderly patients under the term "PBL-e." 310 This variant differs in some respects from age-related EBV + LPD in that EBV latency is of type III, it pursues a less aggressive clinical course, it is more commonly seen in extranodal locations (especially the nose), and half of the cases harbor IGH/MYC translocations. Morphologically, this is a rather monotonous immunoblastic/plasmablastic proliferation with no inflammatory background. All cases described possess a CD20 À /CD138 + /MUM1 + /EBER + phenotype and are therefore more akin to PBL rather than to EBV + / DLBCL-e ( Figs. 6A-H) . Its pathogenesis is related to the immunosenescence as part of the normal aging process. 310 
Primary Effusion Lymphoma
Is a distinct type of LBCL, mostly presenting as a lymphomatous effusion in pleural, pericardial, or peritoneal cavities without a contiguous mass, universally associated with HHV-8. 2 It is more commonly diagnosed in HIV + male individuals usually in the fourth decade who are severely immunosuppressed. It accounts for 4% of NHLs in HIV + patients, but appears extremely rare outside this setting (0.3%). Overall, <150 well-documented cases have been reported. 238 The rare HIV À patients tend to be older with immunodeficiency related to solid organ transplantation, aging, or chronic liver disease (hepatitis B, cirrhosis). 238, 282, 311 Half of the patients have preexisting or metachronous Kaposi sarcoma or rarely MCD. In 60% to 70% of cases HHV-8 is accompanied by EBV infection detected by EBER, especially in HIV + patients. 238, 284 However, HHV-8 is considered the driving force in this lymphoma encoding for several homologues with proliferative or antiapoptotic properties. Thus, viral IL-6 promotes angiogenesis and PEL cell survival, whereas viral miRNAs contribute to the plasmablastic features. In addition, LANA, the viral latency-associated nuclear antigen (ORF 73), hinders the function of retinoblastoma protein and p53, 280, 281, 312 the axis LANA/ p53/ mdm2 having been shown to be important for PEL cell survival. LANA also stabilizes b-catenin and activates MYCdependent transcription by promoting its phosphorylation. By virtue of its ability to recruit the p53-related nuclear transcription factor p57, it influences DNA damage response, cell cycle progression, and apoptosis. In contrast, EBV has a restricted latency pattern of gene expression in PEL, with expression of only EBNA-1 and EBERs considered of lesser importance for its pathogenesis. 281 The neoplastic cells are usually seen in cytospin preparations and display an anaplastic, immunoblastic, or plasmablastic morphology with prominent nucleoli. Binucleated or multinucleated cells of HRS type may also be seen. The cytoplasm is abundant and deeply basophilic and may contain vacuoles. 281, 311 PEL cells commonly (83.6%) express CD45 along with plasma cell markers (CD38, CD138, EMA), but lack pan-B-cell antigens (CD20, PAX5, and CD79a), bcl6, and s/cIg. They are often positive for CD30 (83.2%) 238 and HLA-DR but only rarely is there aberrant expression of T/NK-cell antigens or keratins. 313 Aberrant CD3 positivity is reportedly more frequent in cases arising in HIV + patients. 238 At the genetic level, PEL appears to be a post-GC B-cell neoplasm on the basis of somatic hypermutations of IGH genes, 282 as well as frequent somatic hypermutation of the noncoding region of BCL6 gene. 281 Recently, gene expression studies have revealed similarities of PEL to acquired immunodeficiency syndrome immunoblastic lymphoma and multiple myeloma, compatible with a plasmablastic profile 280 linked with the activation of endoplasmic reticulum stress-mediated pathways. 282 PEL lacks MYC, RAS, or p53 alterations. GEP has identified differences in a significant number of genes including many of the MAPK pathway between EBV + and EBV À cases. 280 PEL needs to be distinguished from lymphomatous effusions complicating a tissue-based lymphoma, which by definition are negative for HHV-8 and recapitulate the phenotypic and genotypic features of the underlying lymphoma. 281 In addition, the differential diagnosis includes HHV-8-unrelated PEL-like lymphomas associated with hepatitis C, which involve the peritoneum and pleura and show features of LBCL with retention of B-cell identity. 281 The clinical outcome of PEL is extremely poor, with a median survival of <6 months. 238 Short-term remissions are seen in a subset of patients with CHOP, but combinations of bortezomib with HAART in HIV + patients may mitigate the biological aggressiveness. 282 The frequent identification of CD30 may provide a rationale for its therapeutic targeting in PEL. 238 Extracavitary HHV-8 + Solid Lymphoma ("Solid Primary Effusion Lymphoma" or "Extracavitary HHV-8-associated Large B-cell Lymphoma") Extracavitary HHV-8 + solid lymphoma may represent a separate disease or a variant of PEL without serous effusions. [314] [315] [316] It mainly involves extranodal tissues, such as the lower GI tract, lung, or skin and infrequently the lymph nodes. In rare cases, secondary distant (noncontiguous) lymphomatous effusions may be observed. 280 Like other HHV-8-associated lymphomas, it is commonly associated with Kaposi sarcoma. It arises primarily in HIV + patients. Morphology, immunophenotype, and genetics are similar to classic PEL, except for a higher incidence of CD20 positivity (17%) and a lower incidence of CD45 positivity (74%). In addition, CD138 may be negative (Figs. 6I-N) , whereas Ig light chains (usually l) may be expressed in almost one third of the cases. 315 The majority of cases express EMA (57%) and CD30 (63%), which in combination with the aberrant expression of CD3 (29%) may lead to the erroneous diagnosis of ALCL. 279, 314, 315 Patients with extracavitary HHV-8associated LBCL appear to have slightly better survival compared with classic PEL. 280 
Early Primary Effusion Lymphoma
The second variant is referred to as early PEL and represents an uncommon form of germinocentric solid neoplasia, usually associated with MCD. 284 The affected lymph nodes show features of follicular hyperplasia, in which some follicles are occupied by large cells with plasmablastic/immunoblastic appearance. These cells are CD20 À /CD138 and MUM1 + and are coinfected by EBV and HHV-8. 317 The differential diagnosis includes plasmablastic microlymphoma associated with MCD and germinotropic LPD. In the former, EBV + cells are not always seen, and, when present, they do not colocalize with HHV-8 + cells, being largely distributed in the interfollicular region.
Germinotropic Lymphoproliferative Disorder
It occurs in immunocompetent patients and represents an intrafollicular neoplasia favorably responding to chemotherapy/radiotherapy. At the histologic level the GCs are occupied by clusters of plasmablasts negative for B-cell markers and positive for plasma cell markers, EBV, and HHV-8, while showing monotypic light chain restriction (k or l), as opposed to early PEL. They are, however, oligoclonal or polyclonal by PCR. These plasmablasts have biological features similar to GC B cells (although they are negative for GC markers) as indicated by the presence of mutated IGH genes and IgA class-switch 279, 318 (Table 9 ). Most recently, a case of germinotropic LPD with monotypic cIgM was described further expanding the spectrum of HHV-8/EBV double-positive lymphoproliferations. 319 A hitherto unrecognized variant of germinotropic LPD EBV + /HHV-8 À has also been reported in which the neoplastic cells were CD30 positive and polyclonal by PCR and IHC, while strongly expressing MYC protein, probably as a result of STAT-3 activation. Notably, this variant was characterized by poor response to treatment. 320 Multicentric Castleman Disease MCD manifests clinically as generalized lymphadenopathy with systemic symptoms and follows an aggressive clinical course. The histology resembles that of plasma cell type with hyperplastic and rarely regressed GCs and abundant plasma cells in the interfollicular area. Besides primary cases, cases of MCD associated with other diseases have been described and are often referred to as IL-6 syndrome, a term reflecting the overproduction of IL-6 and its pathogenic role. HHV-8 has been identified in almost all HIV-associated MCD cases but in only 50% of those occurring in non-HIV-associated cases. 321 The high HHV-8 viral load accompanied by the excess levels of certain cytokines such as viral and human IL-6 or human IL-10 may be responsible for the systemic symptoms at presentation. 238 HHV-8-associated MCD cases are characterized by the presence of medium-sized to large-sized cells with plasmablastic morphology scattered predominantly within the expanded mantle zone of variably regressed follicles but also in the interfollicular region. These cells harbor HHV-8, express IgMl (as opposed to interfollicular plasma cells, which are polytypic), but are negative for EBV. 279, 280 In the presence of EBV coinfection, few EBER + cells are seen in the interfollicular region, which, however, do not coexpress HHV-8 (LANA). Plasmablasts are often negative for CD138 or CD38, positive for MUM1/IRF4, and variably positive for CD20. 280 The differential diagnosis of intrafollicular plasmablastic LPDs is summarized in Table 9 . Despite monotypic IgMl expression, the plasmablasts in MCD are polyclonal by PCR. 322, 323 It is postulated that l light chain restriction may facilitate the entry of HHV-8 within the cells. 280, 281 There is experimental evidence that after exposure of human tonsillar cells to HHV-8, LANA is predominantly found in IgMl + /IL-6R + plasmablasts, a situation analogous to that encountered in HHV-8 + MCD. 282 Plasmablasts have unmutated IGH genes consistent with their origin from a naive B cell that has bypassed the GC. 282 The presence of confluent microscopic aggregates of plasmablasts in the mantle zone, the GC, and the interfollicular area has been termed microlymphoma (Figs. 7A-H). However, the use of this term is now discouraged because very few of these cases actually progress to overt lymphoma and the majority of them are polyclonal at the molecular level. 281, 282 Emerging evidence supports the use of rituximab to decrease the likelihood of progression of HHV-8 + MCD to overt lymphoma. 284 
HHV-8 + Large B-cell Lymphoma Arising Within Multicentric Castleman Disease
These are diagnosed when plasmablasts coalesce to large sheets distorting the normal architecture of lymph nodes or spleen and are easily picked up at low power because of IgMl restriction. Only 21 cases have been documented in English literature, 238 almost 75% of which are HIV positive. The phenotype and genotype of these cells is similar to that of HHV-8 + plasmablasts in MCD, suggesting that the latter may precede the development of frank lymphoma. Molecular analysis, however, demonstrates the presence of clonally rearranged IGH genes only in cases of lymphoma. 279 The lymphoma cells may also involve extranodal sites, such as lung, liver, or GI tract and rarely the peripheral blood. 282, 324 The prognosis of HHV-8 + MCD-associated LBCL is poor, particularly in HIV + patients with a 1-month median survival after diagnosis. 284 Antiviral treatment plus bortezomib has been considered as a therapeutic option in these patients. 238 Anaplastic Lymphoma Kinase-positive Large Bcell Lymphoma ALK + LBCL was first described by Delsol et al 325 in 1997 as an aggressive, monomorphous lymphoid neoplasm with immunoblast-like features, a plasmablastic phenotype, and ALK rearrangements. It is a very rare type of lymphoma with <100 cases reported (reviewed in Dojcinov and colleagues 238, 284 ). It shows a male predominance and a bimodal age distribution being diagnosed in adult and pediatric populations. The latter comprise 15% to 20% of all cases. 326 Patients are generally not immunocompromised (one exception is the case reported by Shi et al 327 in an HIV + patient), and there is no geographical distribution. Patients most commonly present with lymphadenopathy, particularly cervical or mediastinal, although a variety of extranodal sites may be involved (reviewed in Dojcinov et al 238 ) . A recent case has been reported in association with IgG4-related disease in the pancreas and gallbladder. 328 Morphologically, it is characterized by a sinusoidal involvement and a cohesive growth, because of which it may be erroneously diagnosed as metastatic carcinoma. 329 Cases with obvious plasmacytic differentiation may also be misdiagnosed as an extramedullary plasmacytoma. 330 Almost half of the patients present with stage IV disease, although bone marrow is only rarely involved. 238 The immunophenotype is characterized by loss of CD20 and CD79a (less often) with retention of CD45 and expression of plasma cell markers (EMA, CD138, CD38, MUM1), but CD30 is negative or focally and weakly positive (Figs. 7I-P). There is often expression of IgA with l rather than k light chain restriction. Aberrant expression of CD4, perforin, or less often cytokeratins may be seen, which raises the differential diagnosis with carcinoma and T-cell lymphoma. EBV and HHV-8 are not present. 331, 332 The cardinal feature is the expression of ALK with a Modified from Gloghini et al. 280 Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation. pattern depending on the underlying translocation. These tumors express the product of a fusion gene incorporating the 3 0 portion of ALK encoding the tyrosine kinase domain. 326 The most common fusion is t(2; 17) (CLTC/ ALK) (p23; q23) in 75% of the cases, which produces a granular cytoplasmic staining (Fig. 7P) because clathrin encodes for a coated vesicle protein involved in intracellular transport. 326 Less common are t(2; 5) (NPM/ALK) (p23; q35) in 10% to 15% of cases, which yields a cytoplasmic plus nuclear staining pattern or t(2;5) (SQSTM1/ALK) or cryptic CEC31A/ALK fusion resulting from complex rearrangements. 326 In these cases the pattern of ALK IHC is also granular cytoplasmic. In addition, case reports of 5 0 ALK gene deletion, duplications of ALK/ additional copy of chromosome 2, complex karyotype with 2 independent ALK translocations [t(X; 2)(q21;p23) and t(2;12)(p23;q24-1)] producing a granular cytoplasmic ALK positivity, or t(2;5) (SQSTM1/ALK) (p23.1;q35.3) associated with diffuse immunoreactivity have been reported. 326, 333 Experimental evidence underlies the role of ALK fusion genes in disease pathogenesis. 326 ALK chimeric proteins allow for constitutive activation of the ALK tyrosine kinase independently of ligand binding, with consequent unchecked activation of downstream effectors including STAT-3. p-STAT-3 has been documented in all cases, which may be responsible for the upregulation of MYC protein in the absence of MYC translocations. 334 MYC gains/amplifications, however, are identified in 60% of the cases. The relevance of the ALK/STAT-3 pathway in the pathogenesis may be exploited for therapeutic purposes. Indeed, short-term responses to ALK inhibitors have been reported. 238, 333, 335 The biological aggressiveness of this lymphoma may be mediated by the overexpression of antiapoptotic proteins (survivin, BCL-XL) resulting from STAT-3/STAT-5 activation. However, the degree of STAT phosphorylation may differ among the variant ALK fusion proteins being lower in the common CLTC/ALK fusion. 238 An algorithmic approach to the differential diagnosis of the plasmablastic group of lymphomas is presented in Figure 8 .
GRAY ZONE LYMPHOMAS (UNCLASSIFIABLE LARGE B-CELL LYMPHOMA)
This term refers to diagnostically difficult cases of aggressive B-cell lymphomas lying at the interface between DLBCL and cHL or BL. 167 2 These categories were created to maintain for clinical and biological purposes the "purity" of well-defined histologic categories.
Unclassifiable Large B-cell Lymphoma-Diffuse Large B-cell Lymphoma/Classical Hodgkin Lymphoma
BCLu-DLBCL/cHL is mostly diagnosed in Western countries. Patients usually (80%) present with mediastinal disease but, on occasion, involvement of nonmediastinal lymph nodes is seen. 336 There may be involvement of lung (by direct extension), liver, spleen, and bone marrow, but, in contrast to PMLBCL, nonlymphoid organs are rarely involved and the disease is more frequent in young men. Nonmediastinal cases are characterized by older age at presentation, higher propensity for extranodal or bone marrow involvement, and advanced stage, although it is a less bulky disease. 337 Overall, the disease pursues a more aggressive clinical course and has a poorer outcome compared with either cHL or PMLBCL, irrespective of mediastinal or nonmediastinal presentation. PFS appears to be inferior in cases treated with a cHL type of therapy than in those treated with a DLBCL type of therapy. 337 From the morphologic point of view there is typically sheet-like confluent growth of pleomorphic tumor cells embedded in a diffusely fibrotic stroma. Tumor cells may resemble lacunar cells, HRS cells, or centroblasts. Marked variation in morphology within a given case is common as are necrotic areas without neutrophilic infiltrates. Immunohistochemically, there is preservation of the B-cell program (ie, expression of the transcription factors BOB1, OCT2, PAX5) plus expression of "cHL markers" CD30 and/or CD15 (Figs. 9A-H) . SIg is absent and "markers of PMLBCL" such as MAL and CD23 are seen in a proportion of cases. 336 Recently, an IHC scoring system has been proposed to assist the differential diagnosis among cHL, BCLu, and LBCL using markers traditionally associated with cHL (assigned a score of + 1) and markers reflecting the B-cell program (assigned a score of À1).
Scores at one extreme or another likely represent cHL (+ 4 to + 6) or LBCL (À3 to À 6), whereas BCLu cases tend to exhibit a broad range of intermediate scores (À4 to + 3). 338 The histopathologic and immunophenotypic spectrum of this type of lymphoma has been detailed by Gualco et al 338 Based on the findings of 10 cases, the authors recognize 4 patterns. In pattern 1 the morphology is consistent with cHL but IHC shows CD30 with or without CD15 expression, along with strong and diffuse immunopositivity for CD20 and/or CD79a and/or CD45. In pattern 2 the morphology is consistent with PMLBCL but the immunophenotype is characterized by CD30 (strong and diffuse) and CD20 expression, whereas CD15 and CD45 may be positive or negative. In pattern 3 (the commonest pattern) there are areas of PMLBCL/DLBCL juxtaposed to areas of cHL or features of PMLBCL but with many HRS cells. The immunophenotype is characterized by expression of CD45, CD20 (strong and diffuse), CD30 (either focal or diffuse) and strong expression of at least one of the transcription factors BOB1, PAX5, OCT2, whereas CD15 may be positive or negative. EBER may be positive as well. Pattern 4 corresponds to composite lymphoma with areas of cHL and PMLBCL in the same lymph node or in different lymph nodes, either synchronously or metachronously involved. Many authors however, argue against including composite lymphomas within the BCLu-DLBCL/cHL category. 2, 7 It is of interest that 6 of 7 cases in the study of Gualco et al 338 expressed CD23 and 5 of 9 cases p63. The latter was seen in cases resembling cHL. All 10 cases lacked MYC, BCL2, and BCL6 rearrangements as assessed by FISH. The epigenetic profiles examined by Eberle et al 339 appear to be intermediate between cHL (de novo hypermethylation) and PMLBCL (de novo hypermethylation and hypomethylation) but distinct from DLBCL. In addition, HOXA5 hypomethylation seems to be exclusively identified in BCLu-DLBCL/cHL. The genetic features include amplification of REL (2p16) (33% of cases), alterations in JAK2 (9p24) (55% of cases), MYC (8q24) gains (27%), and rearrangement of CIITA (16p13) 340 underlying the "plasticity of mediastinal BCLu-DLBCL/cHL not only on morphologic and immunophenotypic but also on molecular grounds." 341 Unclassifiable Large B-cell Lymphoma-Diffuse Large B-cell Lymphoma/Burkitt lymphoma These are aggressive B-cell lymphomas that share morphologic, immunophenotypic, and genetic features with DLBCL and BL but do not fulfill the diagnostic criteria for either entity. 4 In general there are 2 possibilities: cases may look like BL but the immunophenotype or genotype/karyotype is "too atypical," or ancillary studies are perfect for BL but the cytology is intermediate between BL and DLBCL. The former subset is characterized by bcl2 and often MUM1 positivity, whereas the latter by bcl2 and MUM1 negativity. It should be stressed that this category does not reflect the inadequacies of hematopathologists but acknowledges a gray zone also identified by GEP. 342 However, the intermediate group of GEP and the BCLu-DLBCL/BL are to be clearly distinguished. The intermediate group is defined by a molecular profile distinct from both BL and DLBCL, 343 whereas BCLu-DLBCL/BL is identified by morphologic, IHC, and classical genetic grounds. In pediatric population, the diagnosis of BCLu-DLBCL/BL is rare and does not impact on prognosis or treatment. The same holds true for molecular intermediate lymphomas. A plausible explanation is that pediatric "intermediate lymphomas" represent true BL, also confirmed by the more frequent presence of IG/MYC fusion and the absence of BCL2 breaks compared with adult cases and are classified by GEP as intermediate because of secondary changes and/or a stringent bioinformatics approach. 343 In adults, aggressive B-cell lymphomas lacking typical BL morphology and immunophenotype can be briefly divided into 4 genetic categories according to their MYC status: Ig/MYC-positive mature aggressive B-cell lymphomas with simple karyotype lacking typical BL features, IG/MYC-positive mature aggressive B-cell lymphomas with complex karyotype lacking BL features, non-IG/ MYC-positive mature aggressive B-cell lymphomas, and DH-positive mature aggressive B-cell lymphomas. Most BCLu-DLBCL/BL cases fall within the latter 2 genetic categories. Cases of typical DLBCL harboring a MYC break or typical BL cases negative for MYC rearrangement by FISH are excluded from BCLu-DLBCL/BL. This is a rare diagnosis in adults accounting for no more than 5% of aggressive B-cell lymphomas. The disease is often at advanced stage at presentation (62%) with a high IPI (54% of cases) and bone marrow, extranodal site, or CNS involvement. 344 It is a very aggressive type of lymphoma with a median OS of 9 months and a 5-year OS of 30%. This biological aggressiveness is thought to be related to the presence of MYC abnormalities. 345 Although the optimal therapy remains to be determined, patients are usually resistant to R-CHOP or to BL type of treatment. The only feature discriminating between long-term and short-term survivors is reportedly IPI. 344 From a morphologic point of view, they are characterized by a higher degree of pleomorphism and a lower number of intermediate-size cells than BL, coagulative necrosis, "a starry-sky" pattern often partial, and lack of amphophilic cytoplasm. At the phenotypic level, the neoplastic cells are often of GCB type (68%), although bcl6 may be negative, bcl2 is positive in 50% of the cases, MUM1 is positive or negative, and Ki67 index is <95% (median 80%) 345 (Figs. 9I-P) . The genotype is characterized by a higher frequency of MYC rearrangements (33% to 91%) and MYC positivity by IHC, but a lower frequency of BCL6 rearrangements than DLBCL. These MYC abnormalities are mostly complex (Z6 abnormalities by array CGH), and MYC translocations often do not involve the IGH locus but often involve the IGL loci or non-IGH genes such as BCL6, BCL11A, PAX5, and IKAROS. 61 MYC abnormalities are often accompanied by BCL2 rearrangements (DH, MYC/BCL2 17% to 75%) or rarely BCL6 rearrangements (DH, MYC/BCL6 7.6%). The overall incidence of DH/TH abnormality is 32% to 78%. 11 MYC rearrangement is the only abnormality in 15% of cases (so-called SHL), whereas 42% to 65% of cases do not harbor an MYC rearrangement. The latter is, as expected, more frequently recorded in MYC overexpressing (> 40%) cases, which are often CD10 and bcl2 positive and display a high proliferation index. 336, 342, 345 SHL cases do not seem to fare worse than DHL cases in contrast to the situation in DLBCL, at least in some studies. 74 It is therefore obvious that neither MYC rearrangement nor even MYC immunopositivity is a prerequisite for the diagnosis of BCLu-DLBCL/BL. 336, 345 However, adult cases with a differential diagnosis between BL and BCLu-DLBCL/BL should be diagnosed as BCLu irrespective of other features if they harbor an MYC break in addition to BCL2 rearrangement or BCL6 rearrangement. Table 10 summarizes the phenotypic and genotypic features of BCLu-DLBCL/BL as compared with DLBCL and BL.
Double-hit Lymphoma
DHLs are defined as B-cell lymphomas with concurrent MYC and BCL2 or BCL6 translocations detected by FISH or standard cytogenetics. 2, 342 Rare cases harbor MYC rearrangement with other chromosomal translocations such as BCL3, PAX5, or CCND1. 342, 346 At present, it is not clear whether cases with MYC amplification or copy number gains should be included in the DHL group. For such cases the term "atypical DHL" has been used, 347 and their behavior appears to be as aggressive as that of conventional DHL cases. 67, 348 The genetic variation has been detailed in 2 recent studies, 347, 349 and despite the differences recorded between the 2 investigations, it is agreed that MYC/BCL2 is by far the most common abnormality, its incidence rising up to 77% 349 or 87% 347 within the DHL group. It should be stressed that DHL is not a histologic diagnosis, as it may also be seen in follicular lymphoma (up to 20% to 40% of cases, usually transformed, but even low grade), MCL, or lymphoblastic lymphoma. However, most patients have either BCLu-DLBCL/BL (45% to 60%) or DLBCL. 345, [348] [349] [350] [351] [352] At present, it is not clear how to classify these cases because the 2008 WHO classification recommended that upon the identification of DH abnormality the diagnosis should be BCLu-DLBCL/BL. 2 The incidence of this alteration is estimated to be around 10% (5% to 16%) among DLBCL cases as determined by FISH but increases up to 20% 351 or even 78% 342 within the BCLu-DLBCL/BL group. This incidence, however, may be overestimated because, in some studies, the definition of BCLu was based on the "DH" criterion. 78 Clinically, there is a male preponderance (M/F: 2/1) and the median age is 60 years (17 to 87). Patients usually present with features of high tumor burden, advanced stage, increased LDH, high IPI, B symptoms, and CNS, extranodal, or bone marrow involvement. However, no clinical feature is specific for DHL. Median survival is <2 years with only 33% of the DLBCL patients achieving long-term survival. 352 This biological aggressiveness is thought to reflect the synergism between the proliferative activity of MYC and the antiapoptotic activity of BCL2 and does not appear to be influenced by histology. 351 Cases with MYC amplification/BCL2 rearrangement, MYC rearrangement/BCL2 amplification, or BCL2 rearrangement and an extra MYC signal are not prognostically different from traditional DHL cases. 353 The immunophenotype is of the GCB type (98% of the cases) with bcl2 and CD10 positivity and usually complex karyotypes. In the minority of cases with non-GCB phenotype, bcl2 is negative, MUM1 is positive, and the karyotype tends to be less complex. Finally, p53 mutations are frequent (as opposed to MYC/BCL6 DHL) and there appears to be a synergism with bcl2 overexpression. 354 Remarkably, the cooccurrence of p53 mutation in MYC/BCL2 DHL appears to mitigate the biological aggressiveness, whereas single p53 or BCL2 abnormalities confer poor prognosis to MYC-rearranged cases. 107 It is worthy of note that DHL is responsible for a substantial number of relapses without GCB DLBCL cases. Off-study treatment of DHL should be dose-intense whenever feasible with current data supporting the use of dose-adjusted R-EPOCH plus CNS prophylaxis. 44 On comparing MYC/bcl2 double-positive LBCL (DPL), that is, LBCL with concurrent overexpression of MYC and bcl2, with FISH-defined MYC/BCL2 DHL the following differences are noted. First, DPL are more common (21% to 34% of de novo LBCL cases, 45% of relapsed/refractory DLBCL) 355 than cytogenetic DHL because amplification, mutation, and miRNA-dependent mechanisms also result in overexpression of the proteins, besides translocations. Therefore, DPL are not equivalent to DHL/THL even if 80% to 90% of DHL/THL are also DPL. 342 Issues aggravating the disparity between the 2 groups are the variation in the cutoff values used to determine MYC and bcl2 positivity (usually Z40% for MYC and Z70% for bcl2) 21, 22, 85 and the false-negative bcl2 IHC in the presence of BCL2 rearrangements because of a point mutation in the epitope recognized by the commonly used anti-bcl2 124 antibody. The second major difference is that in contrast to MYC/BCL2 DHL, 63% to 76% of DPLs are of non-GCB phenotype. 21, 22, 85, 344 Third, although DPLs are associated with multiple adverse clinical parameters 356 after adjusting for IPI, MYC rearrangement, or COO, outcomes are inferior to nonoverexpressing MYC and bcl2 cases, particularly within the high-risk group 357 but not as poor as in cytogenetic MYC/BCL2 DHL. 21, 22, 74, 78, 85, 344 It has been proposed that MYC/ BCL2-adjusted IPI is a better discriminator of patients within the high-risk group than IPI. 358 The prognosis of DPL cases as related to COO is debatable. 22, 24, 344 The relationships between BL, BCLu-DLBCL/BL, DPL, DHL, and DLBCL are depicted in Figure 10 .
MYC/BCL6 DHLs account for 8% of all DHL/THL B-cell lymphomas and 2% to 8% of DLBCL cases. 78, 102 The median age at presentation is 83 years being distinctly uncommon in children. They tend to affect women who frequently present with extranodal involvement (including CNS), stage IV, and low to indermediate IPI. The majority (B60%) belong to BCLu-DLBCL/BL type (the remaining are DLBCL). 80 The phenotype is of the GCB type (B80%) and the median Ki67 index is 98% (35% to 100%). Compared with MYC/BCL2 DHL they are less often CD10 positive, are usually MUM1 positive but bcl2 negative (B80%), and cytogenetically less complex. IGH is often the translocation partner for MYC (57%) and for BCL6 (50%). 80 Overall, the morphology, immunophenotype, and genetics are closer to BL than to DLBCL. 359 They are aggressive with a median survival of 9 months, 80 although their prognosis may not be equivalent to that of MYC/ BCL2 DHL. 102 Looking at MYC/bcl6 DPL, they are more often of GCB phenotype compared with MYC/bcl2 DPL and are associated with more favorable outcome unless accompanied by bcl2 overexpression. 102 Regarding the prognostic factors for DHL patients, there are 2 recent large studies enrolling in total 440 patients. In the study of Oki et al 359 survival is determined by performance status and bone marrow involvement, whereas in the study of Petrich et al 346 increased white blood cell count, increased LDH levels, advanced stage, and CNS involvement adversely impacted on survival. An earlier study 297 identified BCLu morphology, high IPI, performance status >2, age above 60 years, and bcl2 expression associated with worse prognosis. Interestingly, cases in which MYC is translocated to IGH (50% to 70%) fared worse than those with non-IGH/MYC translocation. 79, 297 Most recently, cases with both MYC and BCL2 CNA were reported to have similar outcomes to MYC/BCL2 DHL or DPL cases. 67 Intriguingly, MYC CNA + cases (7.5%) had similar OS but shorter PFS than those with MYC rearrangement or MYC IHC expression, whereas BCL2 CNA + cases (27.1%) had shorter OS and PFS than those with BCL2 rearrangement or bcl2 expression. BCL2 CNAs were more frequent within the non-GCB subgroup. However, no difference between BCL2 or MYC gain (3 to 4 copies) or amplification (Z5 copies) was recorded. 67 THLs are defined by the presence of concurrent translocations affecting MYC, BCL2, and BCL6. They account for 16% of cases within the DHL/THL group. Clinically, they show a striking male predominance and a predilection for older age (45 to 80 y), the median age at presentation being 64 years. 360 A subset of patients have antecedent or concurrent follicular lymphoma. Lymph nodes are involved along with extranodal sites and frequently bone marrow. Overall, they resemble more MYC/ BCL2 DHL. They are clinically aggressive with poor response to chemotherapy irrespective of the histologic type. However, a subset of patients may be salvaged by chemotherapy, followed by stem cell transplantation. 360 Histologically, they are diagnosed as BCLu-DLBCL/BL or DLBCL and rarely as follicular lymphoma or lymphoblastic lymphoma. The immunophenotype is characterized by CD10 positivity, bcl2, FOXP1, and MYC protein (usually high) positivity in all cases, whereas bcl6 and MUM1 are also expressed in the majority of cases. The proliferation rate is high (70% to 100%) apart from cases of follicular lymphoma in which it may be as low as 30%. 360 TdT and T-cell markers are negative. THLs belong to GCB type according to most algorithms. The uniform FOXP1 expression may be related to MYC translocation, which inhibits the transcription of micro-RNA34a known to repress FOXP1 and has been shown to correlate inversely with MHC class II genes. 361 As such, FOXP1 may be considered as a contributor to both lymphomagenesis and biological aggressiveness in these lymphomas. IGH is the most frequent translocation partner for MYC (47%), followed by IGL and BCL6. BCL2 almost exclusively fused with IGH (91%), whereas for BCL6 the translocation partners are highly diverse. 360 A case of THL with BCLu-DLBCL/BL has been reported displaying a novel complex karyotype including t(2;3)(q21;q27), t(8;14)(q24;q32), and t(14;18)(q32;q21). 362 From a clinical and pathologic point of view, what is most important is how to suspect and identify DHL and THL cases. It has been recommended that the combination of GCB phenotype and a brisk proliferation rate may enhance our chances of identifying a DHL/THL. However, Ki67 immunostaining has not proved to be suitable as a means to prescreen LBCLs for DH/TH abnormalities, because by using 75% as the cutoff for a brisk proliferation rate, as many as a quarter of DHL/THL will be missed. 363 In addition, if IHC is used to detect MYC and BCL2 abnormalities, 30% of MYC/BCL2 DHLs will be missed 23 on the basis of 40% and 50% cutoff values for MYC and bcl2 overexpression. In fact, it has been proven that by using any cutoff for MYC and bcl2 protein expression IHC is neither specific nor sensitive enough to be used as a surrogate for FISH, despite the high concordance between the 2 methods. 364 It, therefore, becomes obvious that there are no clinical or biological clues predictive of a DHL/ THL, and the identification of these lymphomas requires the relatively liberal use of FISH testing for MYC abnormalities as the first step. 342 In this context, it has been recommended to screen all cases of DLBCL or BCLu-DLBCL/BL for MYC translocations using first a FISH break-apart probe and if this is negative proceed with a fusion probe. 350 If MYC translocations are identified the next step is FISH for BCL2 translocations regardless of proliferation or bcl2 expression, and if this is negative one should proceed with FISH for BCL6 translocations. 352 Alternatively, we may test cases with a high likelihood of harboring an MYC translocation such as immunoblastic DLBCL, GCB DLBCL, and follicular lymphomas, particularly transformed, as well as MYC-positive cases by IHC with >30% positive cells. However, this approach is not 100% safe and some cases of DHL/THL may be missed.
CONCLUSIONS
The great diversity of aggressive LBCLs renders their diagnosis often challenging. Histologic classification is imperative for prognostication and therapeutic purposes and is currently based on the integration of morphology, detailed immunophenotype, and clinical information. Ancillary techniques are not yet established as a requirement for the diagnosis of DLBCL. An initial IHC panel should include, besides B-cell and T-cell markers, CD5, cyclin D1, CD30, bcl2, bcl6, CD10, CD30, plasma cell markers, EBER, and MYC. The presence of high MYC immunopositivity should prompt search for MYC rearrangements. MYC-rearranged cases should be tested for BCL2 and BCL6 rearrangements because they may need alternative treatment. BCLus are identified by morphology and phenotype; however, the diagnostic criteria that might qualify for an entry into this entity may need to be refined. MYC and bcl2 double-expressing LBCLs also merit identification, although there is less aggreement upon the clinical utility of their recognition. High throughput technologies have fostered our knowledge of the genetic landscape by providing a comprehensive view on the genes or pathways that are disrupted secondary to molecular alterations. This information is poised to refine histologic classification and contribute to significant improvements in outcome uncovering potential therapeutic targets. Undoubtedly, the standardization of COO determination and new mutational data indicating which agents should be prioritized for clinical testing will sustain tailored therapy for refractory/relapsed DLBCL cases in the foreseeable future.
